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Abstract
Increasing numbers of old and sick patients who are no longer eligible for pro-
longed invasive implantation surgery have encouraged many researchers to inves-
tigate the development of a Mechanical Circulatory Support (MCS) device with
more reliability and less possible invasive complications, which would benefit the
majority of patients. This thesis will test experimentally and numerically the
feasibility of installing an MCS device, as a bridge to destination, in the descend-
ing aorta, in a series configuration with the heart. To this end, a multi-chamber
Simulator of the Cardio-Vascular blood-flow Loop (SCVL) was designed to sim-
ulate the in-vitro flow rates, pressures and other parameters representing normal
and diseased conditions of the human cardiovascular system. The multi-chamber
SCVL includes models for all four chambers of the heart, and the systemic as well
as the pulmonic circulations. Next, a comprehensive study was conducted using
the SCVL system to compare the novel in-series placement of the pump, in the
descending aorta, with traditional in-parallel placements. Then, a comprehen-
sive numerical study was conducted using the modified Concentrated Lumped
Parameter (CLP) model developed by the same team. The numerical results
are compared and verified by the experimental results under various conditions.
The results for the pump installed in the descending aorta show that the pres-
sure drop, upstream of the pump, facilitates the cardiac output as a result of
after-load reduction. However, at the same time the generated pressure drop at
the proximal part of the descending aorta induces a slight drop in the carotid
perfusion which will be autoregulated by the brain in a native system. Further,
the pressure rise downstream of the pump improves the blood perfusion in the
renal artery. The pulse wave analysis show that the placement of the pump in the
descending aorta leads to improved pulsatility which is beneficial for end-organ
functionality in the native cardiovascular system.
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Subscripts
ac atrium compression
af atrium filling
ao aortic
arao aortic arch artery
asc ascending
ca carotid
cereb cerebral system
des descending
dia diastolic
f frictional action
kid kidneys
la left atrium
lol lower limb
lv left ventricle
lv0 initial left ventricle
mc mean circulatory
mean mean
mi mitral
p effect of pressure force
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pat pulmonary arteries
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po pulmonary
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rv0 initial right ventricle
s systemic
v
sas systemic artery sinus
sar systemic arteriole
sat systemic arteries
scp systemic capillary
ivn inferior vena cava
svn superior vena cava
sys systolic
ti tricuspid
vc ventricular compression
vf ventricular filling
Greek
µ first viscosity coefficient
ρ density
Abbreviations
AoP aortic pressure
Ax axial rotary pump
bpm beats per minute
BLDC brushless direct current motor
C compliance
CaP carotid pressure
Ce centrifugal rotary pump
CHF congestive heart failure
CVD cardiovascular disease
CO cardiac output
D displacement
DA descending aorta
EDP end-diastolic pressure
ESP end systolic pressure
EDP end diastolic pressure
F flow-meter
He helical rotary pump
Hyd hydrolic bearing
HR heart rate
vi
L intertance
LA left atrium
LAP left atrium pressure
LM linear motor
LOS low output syndrome
LV left ventricle
LVAD left ventricular assist device
LVP left ventricular pressure
LVV left ventricular volume
Ma magnetic bearing
MCS mechanical circulatory support
Me mechanical bearing
PaP pulmonary artery pressure
PM permanent magnet
POP pump operation point
PT pressure transducer
PV pressure-volume
Q flow-rate
QI flow index
R resistance
RA right atrium
RaP radial aortic pressure
RAP right atrium pressure
rpm revolution per minute
RV right ventricle
RVP right ventricular pressure
RVV right ventricular volume
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Chapter 1
Introduction
Cardiovascular System Physiology
As shown in Figure 1.1, the human cardiovascular system consists of the following
components: heart, systemic circulation and pulmonary circulation.
1.1 The Heart
The heart is the main component of the cardiovascular system. Its key role is
to pump the oxygenated blood into the systemic circulation and de-oxygenated
blood into the pulmonary circulation. The heart in the human body has a cone-
shape and it is divided into left and right sections each representing an individual
pump. Both left and right sections are further separated through a common wall
and a valve into two sections. The upper sections are called the atria and the lower
sections are called the ventricles. The right atrium and the left atrium are acting
as active conduits of ventricles whereas the right ventricle and the left ventricle
are acting as the major pumping activators. As shown in Figure 1.2, the right
atrium is located in the top right part of the heart and receives de-oxygenated
blood from the superior vena cava, inferior vena cava and coronary veins. The
1
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Figure 1.1: Schematic diagram of cardiovascular system. From: R.J. Levick [1]. An Intro-
duction to Cardiovascular Physiology, 2003.
right atrium is provided with a very thin wall and it is highly distensible, so
it can accommodate a substantial level of de-oxygenated blood from the entire
cardiovascular system.
The right atrium chamber is connected to the right ventricle chamber through
the tricuspid valve. The right ventricle in contrast to the right atrium has a thick
wall which is around 0.5 cm in thickness. The de-oxygenated blood from the
right ventricle is pumped into the pulmonary loop through the pulmonary valve
for a refinement process inside the lungs. Fresh oxygenated blood enters the left
atrium and then through the mitral valve is directed into the left ventricle. Due
to the high level of resistance in the systemic circulation, the left ventricle is
required to provide a higher level of energy to expel the oxygenated blood into
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Figure 1.2: Structure of human’s heart. From: R.J. Levick [1]. An Introduction to Cardio-
vascular Physiology, 2003.
the systemic circulation. As a result, the left ventricle is provided a wall that is
about three times thicker than the right ventricle, as shown in Figure 1.2. The
pressure generated during the systolic phase in the left ventricle (120 mmHg)
is about 5-7 times higher than that of the right ventricle (15-20 mmHg). The
oxygenated blood from the left ventricle is pumped into the systemic circulation
and the coronary branches through the aortic valve.
The expansion (diastolic phase) and contraction (systolic phase) of the atrium
and ventricular chambers in the alternating phases of filling and ejection are
regarded as the cardiac cycle. In one cardiac cycle, both ventricles work in
a series configuration. As a result, the same amount of blood passes through
both of the ventricles unless there is a leakage through the ventricle or atrium
chambers. Each cardiac cycle, for an average human in resting condition, lasts
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approximately 0.9 sec which is equivalent to 67 beats per minute (bpm). Each
cardiac cycle is divided into four phases:
• Filling phases (Diastole)
• Isovolumetric contraction phase
• Pumping phase (Systole)
• Isovolumetric relaxation phase
1.1.1 Filling Phase (Diastole)
The filling phase in a resting condition lasts about 0.5 sec and is subdivided
into passive and active phases. During the passive phase, the tricuspid and the
mitral valves are open, whereas the pulmonary and the aortic valves are closed.
During the passive phase, the blood through the tricuspid and the mitral valves
is directed into the right and left ventricles respectively. During the active phase,
the atriums are contracted. The artruim contraction contributes about 20% of
the filling phase and is reflected as a small bump just before the ascending limb
of the left ventricle and the right ventricle pressure waveform. Figure 1.3 presents
the left ventricular pressure waveform in a clinical setting for an adult human in
a resting condition [2]. Left ventricular end-diastolic pressure (LVPdia) and right
ventricular end-diastolic pressure (RVPdia) are measured upon the closure of the
mitral and the tricuspid valves respectively. Left ventricular end-diastolic volume
(LVVdia) and right ventricular end-diastolic pressure (RVVdia) are measured when
ventricles reach their maximum volumes at the end of the filling phase.
1.1.2 Isovolumetric Contraction Phase
The isovolumetric contraction phase follows the atrium contraction phase. When
the pressure in the ventricles is above the atrium internal pressure, the tricuspid
and the mitral valves are closed to avoid any backflow into the atriums. At
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this stage, due to the existing high tension in the ventricles, the pressure in the
ventricles starts rising, whereas the volume remains constant for a few seconds.
The maximum pressure in the left and right ventricles before the beginning of
the ejection phase are called the left ventricular end-systolic pressure (LVPsys)
and the right ventricular end-systolic pressure (RVPsys).
1.1.3 Pumping Phase (Systole)
The pumping phase triggers when the internal pressures of the right ventricle and
the left ventricle exceed the pulmonary and the aortic pressures respectively. At
this point, both the pulmonary and the aortic valves are forced to open leading
to trigger the ejection phase. Upon the ejection, the internal right ventricle and
left ventricle pressures begin to drop and become lower than the pulmonary and
the aortic artery pressures respectively. However, due to the high energy level
of the ejected flow, the aortic and pulmonary valves are not closed instantly.
By increasing the adverse pressure, the flow momentum begins to fall causing
retrograde flow into the ventricles and ultimately the closure of the aortic and
pulmonary valves.
Figure 1.3: Clinical LVP waveform in controlled condition, From: E. I. Cabrera Fischer et
al. [2]. Endothelium-dependent arterial wall tone elasticity modulated by blood viscosity, 2002.
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1.1.4 Isovolumetric Relaxation Phase
The isovolumetric relaxation phase occurs after the ejection phase. During this
phase all four valves are closed and the pressure falls down sharply due to the
elastic recoil of the heart chambers. This continues until the pressure in the
ventricles becomes lower than the pressure in the atriums. At this point, the new
cardiac cycle begins again by opening the mitral and the tricuspid valves refilling
the atriums.
1.1.5 Frank-Starling Law
The Frank-Starling law states that the contactile energy of an intact heart is
proportional to the pre load pressure in the ventricle chambers. It is shown in
Figure 1.4, for an intact heart, whereby an increase in Central Venous Pressure
(CVP) or Right Atrial Pressure (RAP) results in a higher level of stroke volume.
This can be explained as follows, an increase in the CVP leads to a subsequent
rise in the left ventricular pressure, causing an increase in the distension of the left
ventricle myocardial cell. Starling demonstrated that the contractile energy of
the myocardial cell is proportional to the initial length of the myocardial cell [3].
Therefore, any variation occurring in the CVP level results in different levels of
Cardiac Output (CO) and Stroke Volume (SV).
1.2 Systemic and Pulmonary Circulation
As shown in Figure 1.1, the objective of the systemic circulation is to distribute
the oxygenated blood from the heart to the whole human body and collect the
de-oxygenated blood from the body and send it back to the heart. The systemic
circulation starts from the left ventricle chamber and it continues to the ascend-
ing aorta until it reaches the aortic arch. The aortic arch splits into the upper
arteries and lower arteries. The upper arteries are divided further into arteriole
and capillaries branching toward the cerebral system as well as the arms. The
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Figure 1.4: Cardiac output against right atrial pressure representing the Frank-Starling law.
lower arteries are divided further into arterioles and capillaries branching toward
abdominal organs such as the kidneys, liver and the legs. The pulmonary circu-
lation starts from the right ventricle where de-oxygenated blood is sent through
the pulmonary valve to the pulmonary system for blood refinement. Next, the
oxygenated blood from the pulmonary system is sent back to the left atrium.
Both the systemic and the pulmonary circulation systems consist of various
types of vessels with variable characteristics. In the systemic loop, the sinus
aortic artery is connected directly to the left ventricle and its task is to transfer
the oxygenated blood from the heart to the coronary arteries and the ascend-
ing aortic artery. The sinus artery is more distensive and less resistive than the
other arteries. As proximal arteries, including the sinus aorta and the ascending
aorta, progress distally away from the heart, they branch into smaller vessels
called arterioles. Arterioles are less distensive and more resistive. The arterioles
are subdivided into very small and narrow vessels called capillaries. The capil-
lary’s task is to transfer the oxygenated blood into vital cells and collect the de
oxygenated blood from them. Capillaries are highly resistive and the blood flow
in them is much slower than the arterioles. Slow blood flow makes substance
exchange with cells more efficient. Capillaries are eventually connected together
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Figure 1.5: Different types of blood vessel branches present in a native cardiovascular system.
From: R.J. Levick [1]. An Introduction to Cardiovascular Physiology, 2003.
and create venules. As venules progress toward the heart, they turn into highly
distensive veins. Vein vessels from the abdominal part and upper part of the body
converge together and make the inferior vena cava and the superior vena cava
respectively. Figure 1.5 shows the schematic representation of different types
of blood vessel branches present in a native cardiovascular system. There are
two characteristics in vessels that can considerably influence the hemodynamic
behavior of the blood:
• Compliance
• Resistance
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1.2.1 Compliance
As indicated in Equation 1.1, arterial compliance is proportional to the change
in blood volume and inversely proportional to the change in arterial pressure.
Arterial compliance (C) =
Change in blood volume (∆V)
Change in arterial pressure (∆P)
(1.1)
Figure 1.6: Change in the aortic sinus artery during the cardiac cycle of one second. From:
R.J. Levick [1]. An Introduction to Cardiovascular Physiology, 2003.
Compliance is not a fixed parameter throughout the cardiovascular system.
Larger arteries adjacent to the heart are very compliant in size compared to
distal arterioles and capillaries. In a native cardiovascular system, the largest
arteries like the aorta and the iliac have very distensible walls since they are
rich in Elastin. Elastin is an extracellular protein that is six times more exten-
sible than rubber. The aortic artery and the iliac are able to expand by 10%
during systolic phase and hence accommodate nearly 70 to 80% of the cardiac
output. During diastolic phase elastic vessels shrink back (contraction, recoil)
to the normal size and expel the remaining blood to the peripheral system. As
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Figure 1.7: Clinical aortic pressure (AoP) waveform.From: E. I. Cabrera Fischer et al. [2].
Endothelium-dependent arterial wall tone elasticity modulated by blood viscosity, 2002.
a result of distensibility of native vessels the on-off cardiac output is converted
to the continuous pulsatile flow. Vasculature compliance is not a constant value
and is varying through out the cardiovascular systems. Besides, the other factors
discussed earlier such as the age and the pathological condition have significant ef-
fect on vasculature compliance in a native system [1]. During the diastolic phase,
elastically expanded vessels recoil to the normal size leading to the ejection of
the rest of the accommodated blood into the peripheral resistances. Figure 1.7
shows the clinical aortic pressure waveform of an average human in resting con-
dition [2]. The difference between the gradient of the aortic pressure waveform
of the ascending and the descending limbs is evident. A slight oscillation on the
descending limb of the aortic pressure is due to the slight back-flow into the left
ventricle occurring at the onset of the diastolic phase which is regarded as dicrotic
notch (incisura).
As the blood travels distally away from the proximal arteries toward the pe-
ripheral system, the arterial compliance decreases considerably. A decrease in
compliance level of arterioles and capillaries result in a sharp rise in pressure
gradient during the diastolic phase. Figure 1.8 compares the simultaneous clini-
cal radial artery prssure and the sinus aortic artery pressure waveform at resting
condition. It is shown that radial pressure has a sharper gradient during the
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systolic and diastolic phase compared to the sinus aortic pressure. As shown in
Figure 1.8, the end systolic radial pressure (RaPsys) is higher than the AoPsys
, whereas the end diastolic radial pressure (RaPdia) is slightly lower than the
AoPdia.
Figure 1.8: Clinical radial pressure (left panel) and sinus aortic pressure (right panel) wave-
form in controlled condition. From: S. J. Denardo, et al. [4]. Pulse wave analysis of the aortic
pressure waveform in severe left ventricular systolic dysfunction, 2010.
Another factor is the patient’s age. Arterial compliance declines with advancing
age. In elderly people, due to the physiological change in the body, the wall
vessels become stiffer which subsequently increases the heart work. Also, arterial
compliance changes with various pathological conditions.
1.2.2 Resistance
Vessels in a native cardiovascular system resemble a tube with a circular cross
section. According to Poiseuille’s law [1], the resistance in a tube is directly
proportional to L and inversely proportional to r4, where L and r are the length
and the radius of the tube, respectively. Also, in Equation 1.2, η represents the
1 Introduction 12
viscosity of the working liquid.
Resistance =
8ηL
pir4
(1.2)
Proximal arteries adjacent to the heart are highly dominated by the compliance
and they are less resistive than the other arteries. As the blood travels distally
away from the proximal arteries toward the arterioles, capillaries and terminal
arteries, the size of the arteries become significantly smaller. This leads to a
considerable rise in vascular resistance. In the capillaries, an increase in the
resistance leads to a rise in the pressure gradient and subsequently a fall in the
blood flow. As a result, the blood flow in the capillaries is more continuous
compared to the proximal arteries.
In addition, the resistance level in the native cardiovascular system is outo-
regulated and it changes under various physiological and pathological conditions.
So, when the resistance level, in any local vessel, is increased (vasoconstriction),
the blood perfusion drops down and, in contrast when the resistance level is
decreased (vasodilation), the blood perfusion rises up.
1.3 Cardio-Vascular Disease
Cardio-Vascular Diseases (CVD) including coronary heart disease, cerebro-
vascular disease, high blood pressure, peripheral artery disease, rheumatic heart
disease, congenital heart disease and heart failure lead to the highest rate of
death in the western countries. Approximately about 17.3 million people died
from CVD in 2005, representing 30% of all global deaths [5]. Approximately 10
million in Europe and five million people in America are suffering from end-stage
heart failure [6]. Cardiogenic shock and acute myocardial infarction are the most
pronounced forms of heart failure conditions occurring in 4-7% of patients [7].
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1.3.1 Congenital Heart Disease
Congenital heart disease occurs when the heart of an infant is not developed
thoroughly during pregnancy. This can result in various complications. For
instance, in some rare cases just one single ventricle might be developed, which
pumps the blood simultaneously into the systemic and the pulmonary system in
an abnormal pattern. This abnormality can be detected at different stages. In
some cases, congenital heart defects can be diagnosed before child birth. In other
cases the disease is diagnosed a couple of years after birth. In fortunate cases,
the heart can be remodeled through a surgery and the heart can gain its normal
functionality. In cases with small defects, the heart might gain the functionality
in a natural process. There is a substantial number of patients suffering from
congenital heart defects who are normally aided with pediatric cardiac assist
devices.
1.3.2 Valve Abnormality
Valve disease occurs when one or more heart valves are not operating efficiently.
Valve abnormality can be divided into two categories; valve stenosis where the
valve is not opening appropriately and may result in high resistance and valve
regurgitant where the valve closure incompetence results in a back flow into the
heart. The main treatment for valve abnormality disease is to replace the im-
paired valve with an artificial valve. The two main types of artificial heart valves
are mechanical and biological valves. Mechanical valves are stronger and more
fault tolerant than biological valves but at the same time they cause some un-
wanted impulses due to their inflexible structure. Biological valves normally con-
sist of two or three leaflets made of animal tissues and they are more expensive
than mechanical valves.
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1.3.3 Coronary Disease
Coronary disease occurs when the coronary arteries are obstructed by a blood clot
or fatty substances. As a result the myocardium cells suffer from the shortage
of oxygenated blood, which in the long term leads to a gradual depression of
cardiac function. There are various approaches to treat coronary disease including
atherectomy (grinding the plaque), angioplasty (short balloon inflation in the
arteries) or bypass surgery.
1.3.4 Cardiomyopathy Disease
Cardiomyopathy disease occurs when the myocardium cell becomes too weak to
eject the blood out. The main cause of cardiomyopathy is not known (idiopathic).
However, it has been shown that the alcohol or drug abuse can deteriorate the
condition [5]. Cardiomyopathy can be divided further into three categories:
• A dilated condition where the heart wall becomes thin causing further
deterioration of ejection power.
• A stiff condition where the heart wall becomes too thick and the chamber
volume becomes smaller causing deterioration of the compliant character-
istics.
• A hyperterophic condition where the myocardium becomes thick
thereby causing alternation of blood into the myocardium cells.
1.3.5 Low Output Syndrome
Low Output Syndrome (LOS) is considered as a post-operative complication
where the heart temporarily loses its normal cardiac function. The LOS is most
often attributed to open heart surgery shock and can be fixed by using an assis-
tant blood pump to take over part of the cardiac output temporarily. Centrifugal
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pumps and in some complex cases pulsatile pumps are being used as assistant de-
vices during the LOS state. Normally, in three days time the patient will recover
and be weaned from the assistant blood pump.
1.3.6 Congestive Heart Failure
Congestive heart failure (CHF) as a result of different heart diseases is one of
the leading cause of death in men and women alike. Patients with severe heart
failure are breathless at rest and treatment is palliative. More than seven million
people in both continents of North America and Europe are diagnosed with heart
failure condition, among whom nearly 6% are categorized as CHF stage IV [8].
In Germany less than 2% of the population are diagnosed with the sever heart
failure with almost 80,000 new cases annually [9].
The heart consists of two separate sides, each activating as an individual pump.
Thereby, the specific heart failure is associated with either the right or the left
side. CHF condition can be identified whereby the left or the right side of the
heart becomes severely weakened, as a product of other prior cardiovascular dis-
orders, mainly hyepertension, valve abnormality, coronary disease or cardiomy-
opathy.
Right heart failure occurs when the right ventricle fails to expel enough blood
through the pulmonary artery into the left ventricle. If this is the case, the
venous return continues to direct the blood into the right atrium and in a long
term, it will probably cause a blood congestion and edema in the legs. Since
both ventricles are working in a series, a low output from the right ventricle has
a subsequent effect on the cardiac output. If this is the case, the right ventricle
filling pressure becomes high, whereas the left ventricle pressure remains low. Left
heart failure is the most common CHF condition in which the left ventricle is too
weak to expel the blood coming from the pulmonary loop to the systemic loop.
Since again both ventricles are working in series, left ventricle failure results in a
blood congestion in the pulmonary artery and subsequent high filling pressure in
the left ventricle. This makes breathing action very difficult for a patient suffering
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from end-stage left heart failure [10]. In this study CHF is associated only with
the left heart failure condition.
Patients with severe heart failures suffer from renal impairment and pulmonary
hyepertension [11]. The kidneys are one of the crucial organs of the body and
they consume about 6% of the total oxygen and also account for nearly 20% of
the cardiac output. If the heart failure condition is not diagnosed and treated in
the earlier stage of the disease, multiple organ failure may occur leading to early
mortality [1]. Since the heart failure condition is accompanied by symptoms of
variable internal organ disorder, it is difficult to classify the severity of CHF. One
of the best CHF classifications was conducted by the New York Heart Association
(NYHA). It suggested that the CHF condition can be divided into four categories
known as Class I, Class II ,Class III and Class IV [12].
Class I CHF accounts for patients with cardiac disease but without restriction
to physical activity. Class II accounts for patients with cardiac disease with slight
limitation to physical activity. Patients with Class II CHF are comfortable at
rest, however, normal physical activity results in a pain in the chest area. Class
III CHF accounts for patients with cardiac disease with significant limitations
to physical activity, and they are only comfortable at rest. However, even slight
physical activity results in pain in the chest area. Class IV CHF accounts for
patients not able to do any physical activity. In clinical practice, class IV CHF is
considered as the most dangerous state, in which a patient is not able to undertake
any physical activity comfortably and so she/he is bed bound.
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1.4 Treatment of Heart Failure
Depending on the level of the heart failure condition, there are various therapies.
In early-stage CHF, traditional pharmacological treatment can to some degree
prevent the disease. In end-stage CHF, when the patient does not respond to the
pharmacological treatment, surgical intervention including heart transplantation,
total artificial heart implantation, Intra-Aortic Balloon Pump (IABP) and MCS
devices can be suggested.
1.4.1 Drugs
Depending on the type and severity of heart disease, different pharmological
treatments are suggested. Drugs prescribed for early-stage CHF may help cardiac
improvement via a reduction of after-load pressure. As mentioned, the after-load
pressure is attributed to the pulmonary and the aortic artery pressure against
which the right and the left ventricle ejection occur respectively. Therefore, to
expel the blood from the heart into the cardiovascular system, the pressure in
the ventricles needs to exceed the corresponding after-load pressure. The higher
the after-load pressure, the greater the force is required for ejection. Vasolidator
drugs work by reducing peripheral resistance in the pulmonary or the systemic
circulation and result in after-load reduction leading to cardiac improvement [1].
Furthermore, there are other types of drugs such as Nitroprusside or Prostacy-
clin which are commonly used for the treatment of myocardial infarction as well
as hypertension condition [13]. In addition, there are inotropic drugs including
Dopamine and Dobutamine, which are being used to support the failing myocar-
dial muscle [14].
1.4.2 Heart Transplantation
When the patient does not respond to pharmacological treatment, other types
of treatments are suggested. Heart transplantation is the most reliable and well-
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established surgical treatment. At the beginning, due to a wide number of un-
known complications, the rate of survival was limited to some days or weeks.
However right now nearly 85% of recipients are alive at least one year after
surgery [15]. Recently, the first infant recipient in the UK celebrated her 25th
birthday [16]. However, the demand for heart transplantation is more than the
supply, as a result, many of the patients who are on the waiting list to receive
a donor heart may not survive. Among 4,200,000 patients with end-stage heart
failure in both North America and Europe, only small minority of young pa-
tients (≤50 year old) are eligible for the heart transplantation surgery and the
rest are not included in this category. Donor hearts supply meets less than 2%
of the demand of eligible patients and leaves nearly great majority of end-stage
CHF patients under palliative treatment [17]. Further it must be noted that the
heart transplantation is a significantly invasive and prolonged surgery needing
the recipient’s median sternotomy to be cracked and opened. As a result, those
patients who are not in a suitable physical condition may not survive.
1.4.3 Total Artificial Heart
Before heart transplant surgery became the most reliable treatment for end-stage
CHF, considerable efforts were made by many researchers and cardiologists for the
development of a Total Artificial Heart (TAH). The first TAH implant surgery in
the human body was conducted on an end-stage CHF patient in 1968. The device
was in the body of a patient for 64 days before heart transplant surgery [18].
Older versions of TAH such as Jarvik 7 [18] and SynCardia [19] are mainly
pneumatically actuated devices. They are, to some extent, large, heavy and less
efficient. Many of these devices are still under development in various medical
centers. New versions of TAH, such as AbioCor [20] are electrically actuated de-
vices which are normally implemented as a bridge to transplant. They are smaller
in size compared to the pneumatically actuated types and are more efficient. Use
of TAH as a replaced support device in various heart failure cases has shown a lot
of complications, such as bleeding, valve failure and blood clotting. These com-
plications are generally attributed to the large size of the TAH. Therefore, the
1 Introduction 19
Figure 1.9: Schematic diagram of the SynCardia TAH. From: M. J Slepian, et al. [19].
The syncardia (tm) total artificial heart: in vivo, in-vitro, and computational modeling studies,
2013. .
development of a smaller and more efficient support device capable of improving
the action of an impaired heart has been pursued.
1.4.4 Intra-Aortic Baloon Pump
The Intra-Aortic Baloon Pump (IABP) is recognized as one of the established
treatments for end-stage CHF patients. The concept of the IABP was introduced
first by Kolff and Moulopoulos in 1962 [21]. The IABP incorporates a pulsatile
balloon which is normally inserted through the femoral artery and is placed in
the proximal descending aorta. During the systolic phase the balloon deflates
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and lets the blood travel to the peripheral system. During the diastolic phase the
balloon inflates leading to a rise in after-load pressure favoring coronary perfusion.
The balloon is connected to a console by means of a thin catheter. The console
controls the inflate-deflate action synchronously with the heart beat. Although
the IABP is not categorized as mechanical assistance device, it helps the heart
function to improve while the patient is waiting for a donor heart. Immobility is
the main drawback of the device, so the patient needs to be hospitalised to be
put on a IABP during the treatment.
Figure 1.10: Schematic representation of IABP.
1.4.5 Mechanical Circulatory Support
In the USA, the supply of donor hearts only meets about 2% of the demand. The
numbers are similar in percentage for the population of the western world. This
shortfall in supply has resulted in the development of MCS devices as a reliable
transplant alternative. In the past, 80% of CHF cases would have ultimately died.
However, in recent years the increasing the use of MCS devices have significantly
reduced the mortalities [22].
MCS devices mainly consist of a pump that is connected from the heart to
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either the systemic or the pulmonary blood circulation through one graft [23] or
two grafts [24]. The pump directs the blood from the heart to the blood circu-
lation system by extracting kinetic energy from the electrical source. In contrast
to the TAH device which is implanted as an alternative to the heart, the MCS
device is implanted next to the heart and is intended to take over part of the
cardiac function. Normally, this device is assisting one impaired heart chamber.
However, in many cases, if two heart chambers such as the left and the right
ventricles are malfunctioning, two MCS devices operating simultaneously are re-
quired. Depending on the severity of heart failure and also the type of MCS device
used, the end goal of the application of the MCS device can be different. The
application of an MCS device can be classified into three sub-categories including:
• As a bridge to transplant [25].
• As a bridge to recovery [26].
• As a bridge to destination [27].
The application of an MCS device as a bridge to heart transplant has been
crucial in recent years [25]. Only a small number of patients with end-stage CHF
can have heart transplant surgery. Owing to an insufficient number of heart
donors, many patients with end-stage CHF conditions have to wait for cardiac
transplant surgery for more than six months. It is also reported [28] that patients
supported with MCS devices, while on the heart transplant waiting list, have a
higher chance to survive after the heart transplant operation. It is demonstrated
that patients on MCS support have better physical conditions compared to the
ones treated pharmacologically.
The application of MCS devices as a bridge to recovery has been reported in
the study conducted by Frazier et al. [26]. It is demonstrated that using the
MCS device in a number of patients can help them regain the cardiac function
during the support period, therefore the device can be removed without a need
to implant a donor heart. Depending on the age of the patient and the severity
of the disease, the recovery time prior to explantation may vary.
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The application of MCS devices as a bridge to destination has also been re-
ported [27]. Currently, the only alternative solution for heart transplantation in
patients suffering from chronic irreversible heart failure is to implant a permanent
MCS device with minimum complications. Permanent implantation of an MCS
device as a destination therapy has helped a significant number of patients who
could not benefit from a suitable donor heart [27]. An MCS device developed
for prolonged application must satisfy three crucial criteria; long term safety,
efficiency and durability. Meeting the above criteria can help to decrease the
probability of morbidity and mortality. It is reported [29, 30, 31] that the new
generation of continuous MCS devices [23, 32] are more reliable for long term use
due to their simplicity, high efficiency and in particular they are very compact
and their usage results in less morbidity and mortality.
In general, MCS devices are categorized on the basis of their dynamic motion
into Pulsatile [33] and Continuous (rotary) [32, 34]. The latter can be further
categorized on the basis of the rotor structure into axial [32] and centrifugal [34].
The efficiency of an MCS device is determined by its aerodynamic design and
also by the biocompatibility of the inner components.
1.4.6 Pulsatile MCS Devices
Pulsatile MCS devices, regarded as the first generation of MCS devices, can mimic
the native left ventricle and provide pulsatile flow by taking over the function of
the patients own left ventricle. The first pulsatile MCS device implantation was
conducted in 1968. In this operation, a pulsatile MCS device was implanted,
through the left thoracotomy, next to the heart and was bypassed between the
apex of the left ventricle and the descending aorta [35]. Pulsatile pumps normally
employ a flexible diaphragm which is displaced either pneumatically or electri-
cally to produce the pulsatile flow. Use of a displacement mechanism inevitably
increases the volume of the device. Also, the pump consists of two unidirectional
valves to direct the blood from the heart to the aorta and to stop back flow to
the pump.
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The most widely used pulsatile MCS devices have been extracorporeal de-
vices such as the BVS 5000 VAD produced by Abiomed, Inc. (Danvers, MA,
USA) [36] and the Thoratec VAD produced by Thoratec Corporation (Pleasan-
ton, CA, USA) [37]. The rest are intracoporeal devices such as the Novacor LVA
System produced by WorldHeart, Inc. (Oakland, CA, USA) [38]. Newer Pulsatile
MCS devices such as the LionHeart VAD produced by Arrow International, Inc.
(Reading, PA, USA) [39] are totally implantable. Figure 1.11 shows the Thoratec
pulsatile pump from the Thoratec Corporation.
Previoues studies [40, 41, 42] have demonstrated that the pulsatile flow has an
enormous influence on flow circulation physiology of the cardiovascular system.
The pulsatile flow stimulates the blood perfusion as well as oxygenation in vital
organs such as the kidneys and the liver. It can also improve the micro-circulation
in diseased myocardium cells that ultimately leads the cardiac function being
regained. However, the concept of a pulsatile MCS device suffers from serious
drawbacks such as device weight, size, noise and drive line infection. Furthermore,
as a result of the contribution to the number of moving mechanical components in
one unique pulsatile device, the durability of these types of devices is limited to a
few years. The repetitive displacement of the diaphragm in the long term results
in tremendous stress on the moving components. This reduces the distensiblity
of the diaphragm and ultimately leads to the development of some physiological
consequences such as thrombosis formation in the blood system [43].
1.4.7 Centrifugal MCS Devices
Complexity, inefficiency and the large size of pulsatile MCS devices has encour-
aged researchers towards the development of an assistant device with higher ef-
ficiency, smaller size and less moving elements. Centrifugal MCS devices are
regarded as the first generation of non-pulsatile pumps. Centrifugal pumps have
been used for Cardio-Pulmonary Bypass (CPB) and also Extra-Corporeal Mem-
brane Oxygenation (ECMO) Since 1980. The first centrifugal pump used as a
bridge to transplant MCS device was developed in the early 1980s by Golding et
al. [44].
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Figure 1.11: Implantable, intracorporeal version of the Thoratec (IVAD). From: D. J. Farrar
et al. [37], Long-term follow-up of thoratec ventricular assist device bridge-to-recovery patients
successfully removed from support after recovery of ventricular function, 2002.
Figure 1.12: HeartWare centrifugal pump. From: M. S. Slaughter et al. [45], Heartware
miniature axial-flow ventricular assist device design and initial feasibility test, 2009.
In general, centrifugal pumps are employed in various applications to produce
pressure build up rather than flow rate. The centrifugal MCS device has a tita-
nium impeller driven by magnetic coupling. The inlet flow is in parallel with the
rotational axis and the outlet flow is perpendicular to it. The impeller is made
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of a number of vanes that convert the axial velocity into the radial velocity. The
impeller rotating speed in the centrifugal MCS is lower (2000 rpm-6000 rpm) than
the axial MCS (3000 rpm-25000 rpm) [46]. The lower the rotational speed, the
smaller the shear stress on the interacting components of the pump and thereby
the lesser the physiological consequences. Thus, centrifugal pumps are regarded
as highly efficient MCS devices compared to other types of MCS devices. One
of the drawbacks of the centrifugal MCS device is its large size. Implantation
of a large mechanical device into the patient’s body is usually followed by some
complications. In particular, very ill patients can develop severe organ infections,
cancer or neurologic damages which may result in morbidity and mortality [47].
The second generation of centrifugal MCS devices, such as the NEDO PI-601
pump (evolved GyroC1E3) [34] consist of two contacting bearings for holding the
impeller. Use of contacting bearings increases the risk of clotting and thrombus
formation at the contact bearing and thus reduces the reliability of the device for
long term use.
The third generation of centrifugal MCS devices includes DuraHeart [48],
HeartMate III [49] and HeartWare [45], which are more desirable to be used
as a bridge to destination. The third generation of centrifugal MCS devices em-
ploys magnetic and hemodynamic bearings instead of using contacting bearings.
Employment of the magnetic bearing reduces the stagnant spots and hence the
risk of thrombus formation as well as component wear.
In order to reduce the risk of infection inside the recipient’s body, it is preferred
to implant a fully sealed device, with less interaction with blood circulation [50].
As a result, looking for a pump with a smaller size and smaller interacting surface
is preferable. Axial MCS devices are smaller in size compared to centrifugal MCS
devices.
1.4.8 Axial MCS Devices
In general, axial pumps are used for generating low pressure gradients and high
flow rate conditions. This will make the axial MCS devices suitable for many
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pathological conditions with low cardiac output. Axial MCS devices are smaller in
size compared to centrifugal MCS devices. The smaller the size of an MCS device
in the body, the lesser the risk of infection and subsequent post-operative compli-
cations. Figure 1.13 shows the schematic diagram of the DeBakey pump [24]. It is
indicated that the pump consists of an axial impeller rotating inside a concentric
cylindrical housing. The impeller is normally made of titanium and includes a
couple of helical guided vains to lead the flow forward. As shown in Figure 1.13,
a number of small rare earth magnet cylinders are embedded into each blade of
the impeller. The brushless magnet has been developed and used around the
flow tube where the moving part is located. As a result of an inductive magnetic
field between the magnetized blades and the brushless magnet, the impeller spins
and makes the flow move forward. Normally, the impeller rotates at a speed of
8000 -12000 rpm, producing average blood perfusion from 3-6 lt/min against the
physiological resistance. As shown in Figure 1.13, a diffuser is set downstream of
the impeller to convert the swirl velocity produced by the impeller to axial flow
which eventually leads to the conversion of the kinetic energy to static pressure.
The second generation of axial MCS devices integrate two contacting bearings
to hold the impeller. Major off-the-shelf second generation axial pumps include
the Jarvik 2000 (25 ml in volume) [32], the HeartMateII (124 ml in volume) [27]
and the Micromed (30 ml in volume) [51]. Employment of contact bearings
increases the risk of thrombus formation at the bearings and thus reduces the
reliability of the MCS device for long-term use [52].
This problem has been solved by third generation axial MCS devices by imple-
menting a magnetically levitated impeller. Major third generation axial pumps
such as the Incore1 [24] that employ magnetic bearings avoid tremendous friction
force between the impeller and the housing leading to significant noise reduction.
1.4.9 MCS Device Complications
In general, introducing an MCS device into a native cardiovascular system is
followed by a number of physiological variations in the blood circulation which
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Figure 1.13: Debakey axial rotary pump. From: R. Hetzer et al. [24], First experiences with
a novel magnetically suspended axial flow left ventricular assist device, 2004.
may lead to some subsequent complications such as flow-induced haemolysis,
bleeding, infection and thrombus formation in the long-term period [31].
Haemolysis, in medical terminology, is defined as the destruction of red blood
cells. Blood haemolysis levels are attributed with the shear stress and the ex-
posure time of interacting components of an MCS device. Measuring the level
of blood haemolysis induced by the shear stress of mechanical devices is one of
the common approaches for evaluating the effect of MCS devices on physiological
alteration of the blood.
Induced haemolysis can potentially exist for both pulsatile and continuous
MCS devices. However the level of blood haemolysis, depending on the pump
characteristic, may vary. Pulsatile MCS devices, due to their inherent dynamic
mechanism, tend to generate considerable turbulent flow. Particularly, severe
turbulent flow is generated in the vicinity of moving components, such as flexing
diaphragm and the mechanical unidirectional valve. Presence of the turbulent
regime leads to the creation of extra shear stress (Reynolds shear stress) in these
areas and therefore causes an increase to the blood haemolysis level in these
devices [43]. For the continuous MCS devices, increasing the rotational speed
results in an increased shear stress in vicinity of the propeller which may lead to
a significant haemolysis [53].
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Figure 1.14: Thrombus formation in the axial pump after explantation. From: G. S. Allen
et al. [43], The importance of pulsatile and nonpulsatile flow in the design of blood pumps, 1997.
Thrombus formation inside the continuous and pulsatile MCS devices is highly
life threatening. This, in the worst case scenario, may cause thromboembolic
complications in the recipient’s cerebral system. In general, the natural blood
system is laminar unless an artificial device is introduced into the blood circula-
tion system. Thrombus formation is more likely to develop in association with
turbulent flow than laminar flow. As stated earlier, pulsatile MCS devices due
to their inherent dynamic mechanism, tend to generate a considerable turbulent
flow. Development of turbulent flow causes thrombus formation in the pump
chamber, which may gradually accumulate and in some cases may affect the in-
flow and outflow valves [43]. Turbulent flow formation in a continuous MCS
device is highly dependent on the aerodynamic design of the impeller. Normally,
thrombus formation develops downstream from the impeller at the diffuser where
the blood flow is turbulent as shown in Figure 1.14.
The bleeding is one of the more frequent postoperative complications. The
bleeding complications are normally caused after a prolonged invasive implan-
tation surgery in patients with advanced ages. As a result, looking for a less
invasive implantation technique which can be utilized in a variety of patients has
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become a recent area of interest. The use of various anticoagulants in patients
supported with MCS device is another factor that may cause bleeding. Anti-
coagulations are used in recipient’s blood system to avoid the thromboembolic
complications. However, there is a difficulty in choosing the right anticoagulation
protocol which not only can prevent the thrombus formation but also can avoid
the bleeding complications [9].
Infection rate is another MCS device complications occurring normally just
after implantation and may increase with the length of the MCS usage. The
infection complication are caused by various sources mainly wire infection and
MCS pocket infection. The wire infection is due to the skin perforation which
let the microbe and bacteria into the body. The use of Transcutaneous Energy
Transmission (TET) may prevent this problem significantly. The pocket infection
is caused mainly by implantation of large sized MCS devices. This requires highly
invasive tissue dissection surgery which increases the risk of infection. The use of
miniatured MCS device and the implementation of novel implantation techniques
with less invasive surgery may reduce the infection [9].
Technical failure is another highly risk factor complication which is not pre-
dictable and may lead to the death of the patient. Motor and bearing failures
are the most frequent technical complications. Further research is required to
overcome these problems. Inflow graft occlusion can be another technical com-
plication that normally develops in dehydrated patients after MCS implantation.
This is due to the high level of suction in the absence of blood inside the left
ventricle where a lot of myocardial tissue is sucked and accumulated [52].
1.5 Implantation Techniques
Surgical deployment of an MCS device in the native cardiovascular system causes
a variety of hemodynamical alterations to the natural system. There are two
typical techniques for MCS devices implantation:
• Median sternotomy
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• Left thoracotomy
In the median sternotomy technique, the sternum is cracked, opened and the
device is implanted next to the heart. In the left thoracotomy technique, the
device is implanted through a small incision in the left thoracotomy without
breaking the sternum. Both of these techniques are considerably invasive and
require CPB for critically ill patients. It is demonstrated [54] that a prolonged
invasive operation in critically ill patients results in considerable post-operative
complications such as infection, bleeding and renal failure. Development of less
invasive techniques has become a subject of interest recently. There are currently
no cardiac support devices for permanent implantation that can be installed with
minimally invasive surgery, and therefore there is a need for a viable alternative.
1.5.1 In-Parallel Configuration from Left Ventricle to As-
cending Aorta
The most traditional implantation technique for pulsatile and continuous MCS
devices is to implant the device between the apex of the Left Ventricle (LV) and
the Ascending Aorta (AA), in-parallel with the heart, by conducting sternotomy
surgery. Figure 1.15 shows the HeartWare pump [45] in the LV-AA configura-
tion. Studies on the in-parallel LV-AA technique [48, 55, 56] indicated that the
insertion of an MCS device between the left ventricle and the ascending aorta
resulted in a promising hemodynamic improvement in blood circulation system.
However in this technique, the dissection process is prolonged which necessitates
the use of Cardio-Pulmonary Bypass (CPB) during the operation. Having a pro-
longed surgery in seriously ill patients results in some considerable complications
post-surgery such as right ventricular dysfunction, end-organ injury and internal
bleeding [56]. Moreover, long hospitalization after surgery increases the risk of
contacting infectious diseases.
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Figure 1.15: Heartware pump in the LV-AA configuration. From: M. S. Slaughter et al. [45],
Heartware miniature axial-flow ventricular assist device design and initial feasibility test, 2009.
1.5.2 In-parallel Configuration from Left Ventricle to De-
scending Aorta
When compared to the older generation of MCS devices [32, 34] and the pulsatile
VADs [33], the third generation of MCS devices such as Jarvik 2000 [32], Mi-
croMed Debakey [51] and Incor [24] are more desirable for implantation through
the left thoracotomy. This is due to minimal size, weight and low energy de-
mand. Figure 1.16 shows the Jarvik pump which is surgically configured in a
transcardial arrangement within the apex of the left ventricle [23].
In this technique, the device is implanted through a small incision into the left
thoracotomy without breaking the sternum. Then the inflow graft is sewn to the
apex of the left ventricle and the outflow graft is anostomised to the descending
aorta (DA), adjacent to the left atrium, in parallel with the heart [24, 56, 57, 58].
In many cases the MCS implantation procedure through thoracotomy surgery
could be conducted without CPB [56].
The implantation procedure without CPB shortens the time of the operation
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Figure 1.16: Jarvik pump in LV-DA configuration. From: O. H. Frazier [23], Research and
development of an implantable, axial-flow left ventricular assist device: the jarvik 2000 heart,
2001.
considerably and hence reduces the probability of post-operative complications
such as bleeding and infection. Nevertheless recent findings on LV-DA suggest
that this technique may not be hemodynamically optimal in various degrees of
the pump support. It is reported [54, 58, 59] that the outflow graft connection
to the descending aorta results in a reduction in the mean aortic arch flow as the
level of MCS support is increased. This will result in formation of stagnant and
then retrograde flow in the aortic arch which may lead to aortic valve stenosis [46].
1.5.3 In-Series Configuration in Descending Aorta
In both LV-AA and LV-DA in-parallel techniques, the pump operates as a com-
petitor to the left ventricle. A parallel working system improves the cardiac
output by reducing the pre-load. In this approach, the pump can take over part
or the entire heart load. In a series configuration, the entire cardiac output is
delivered through the aortic valve and the device. Negative pressure upstream of
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the pump reduces the after-load pressure to facilitate cardiac output.
In clinical practice, pharmacological treatments such as vasolidators are the
best approach to reduce the after-load pressure in high filling failure condition.
Although the use of vasodilators leads to an improvement to the cardiac output,
in a critically low blood pressure situation, such as cardiogenic shock or post-
cardiac operation, it may lead to the creation of extreme perfusion disturbances
in the abdominal organs.
Recent studies on two temporary paracorporeal MCS devices, inserted percuta-
neously into the descending aorta to prevent cardiogenic shock, suggests that the
descending aorta can be a promising location to install a long-term implantable
MCS device with minimally invasive surgery [46, 53, 60, 61].
(a) (b)
Figure 1.17: (a) Reitan Catheter Pump (RCP) in the descending aorta. From: O. Reitan
et al. [53], Hemodynamic effects of a new percutaneous circulatory support device in a left
ventricular failure model, 2003 (b) Impella axial rotary pump crossing the aortic valve. From:
A. G. Rose et al. [46], Partial aortic valve fusion induced by left ventricular assist device, 2000.
The Reitan Catheter Pump (RCP) is a novel approach among other mechanical
circulatory systems. The RCP consists of two foldable blades embedded inside a
surrounding umbrella-like mechanism cage and an external DC motor (paracor-
poreal MCS). The RCP blades are connected to a DC motor through a rotating
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wire placed inside a flexible catheter. Similar to the IABP, the RCP rotor is
inserted through a small incision in the femoral artery and is advanced towards
the proximal descending aorta. Once the rotor is placed at the right position, the
cage is expanded and the rotor is unfolded. Figure 1.17(a) shows the schematic
diagram of the RCP placed in-series configuration with the heart. The pressure
difference produced across the RCP rotor at 14000 rpm rotational speed is about
24 ± 10 mmHg. The pressure drop generated at the upstream of the pump re-
sults in a reduction of the after-load pressure and subsequent improvement of CO
without the risk of kidney failure that would have occurred by using vasodilators.
Impella Recover is an intra-cardiac axial pump which is being used to pro-
vide short-term assistance for patients with end-stage cardiac failure. The pump
consists of a propeller with a diameter of 4.5 mm. The propeller is driven by
a micro-engine through a flexible cable. The propeller and the electronic driver
are placed inside the inflow cannula, which guides the flow into the ascending
aorta. The pump is inserted through a small incision in the femoral artery and
is advanced into the left ventricle, by crossing the aortic valve, as shown in Fig-
ure 1.17(b). At a propeller speed of 30000 rpm, the maximum flow rate produced
by the Impella is 4.5 lt/min [46]. Clinical findings on an Impella recipient with
hypotensive condition (75/61 mmHg) show that the cardiac output has improved
by up to 2.5 lt/min. When compared to the standard IABP, the Impella pump
exhibits higher hemodynamic performance [46].
Table 1.1 presents the specifications of the available rotary heart assistance
devices as well as their implant configurations in the human body.
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Table 1.1: Specification of available rotary MCS devices
Device ∆P Q D ω Power Dimension Mass Bearing Configuration
Debakey (He) 100-120 5-10 12 7500-12000 10 86× 25 95 Me In-parallel
LV-(AA&DA)
HeartAssist5(He) 100-120 1-10 12 8500-10600 10 71× 30 92 Me In-parallel
LV-DA
Jarvik(He) 100 2-7 11 8000-12000 ≥ 12 55× 25 85 Me In-parallel
LV-DA
Theoratec(He) 100 6.5 - 8000-12000 3-7 55× 25 85 Me In-parallel
LV-AA
IncorLVAD(He) 100 6 13 5000-10000 ≥ 5 123× 30 200 Mag In-parallel
LV-(AA&DA)
MicroVAD(He) 80 4 7 30000 - 50× 12 - Me In-parallel
LV-DA
MagneVAD(He) 100 6 14 12500 5 60× 30 89 Mag In-parallel
LV-DA
HeartMateII(He) 80-100 10 11 6000-15000 10-12 81× 43 281 Me In-parallel
LV-AA
Impella 2.5(Ax,Pe,Te) - 4.5 - 30000 10 65× 4.5 - Me In-series
AA
Reitan(Ax,Pe,Te) 14-34 5 15 10000-15000 1.11 21× 25 - Me In-series
DA
GyroCiE3(Ce) 110-150 5-8 68 2000-2500 - 53× 65 305 Me In-parallel
LV-DA
EvaHeart(Ce) 100 5-9 40 2600 9-10 55× 64 370 Me In-parallel
LV-DA
VentrAssist(Ce) 100 5 16-40 1800-3000 7-8 60 298 Hyd
In-parallel
LV-AA
DuraHeart(Ce) 150 2-10 50 1200-2600 8-13 72× 45 540 Mag In-parallel
LV-DA
Heartmate III(Ce) 135 7 44 2000-5500 ≥ 10 30× 69 535 Mag In-parallel
LV-AA
MiTi(Ce) 100 2-7 34.5 2500-3500 6.5 80× 50 300 Mag In-parallel
LV-DA
∆P: maximum pressure gradient of pump (mmHg), Q: maximum flow-rate (lt/min), D: diameter (mm), ω: rotor speed (rpm), Power (watt), Dimension
(mm×mm), Mass (g), Ax: axial, Ce: centrifugal, He: helical, Pe: percutaneous, Me: mechanical, Mag: Magnetic, Hyd: Hydrolic, Te: temporary usage LV:
left ventricle, RV: right ventricle, AA: ascending aorta, DA: descending aorta.
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1.6 Simulators of the Cardio-Vascular Blood-
flow Loop
The design and development of a Simulators of the Cardio-Vascular blood-flow
Loop (SCVL) which is capable of emulating the characteristics of the cardiovas-
cular system not only can provide one with the required hemodynamic response
but it also avoids number of complications that one may come across in an in-vivo
test. In order to dynamically model a cardiovascular system (whether computa-
tionally or experimentally), the physiological characteristics of each component of
the native cardiovascular system should be investigated at different pathological
conditions. Each part of the cardiovascular system has its own characteristics and
dynamic behavior. As a result, broad knowledge of the hemodynamic behavior of
cardiovascular system in various physiological and pathological states is a major
pre-requisite for developing an SCVL system.
The design and implementation of an SCVL system is motivated by the ne-
cessity and significance of in-vitro tests of various artificial devices such as heart
valves, Ventricular Assist Devices (VAD) and Mechanical Circulatory Support
(MCS) devices prior to in-vivo testing. Earlier versions of SCVL systems were
mostly pulsatile and were driven by stepping motor. These SCVL systems were
mainly developed for the investigation of various heart valves [62, 63, 64]. The
next generation of SCVL systems were developed in order to conduct hydrody-
namic, hemodynamic and haemolysis investigations on cardiac assistance devices
as well as on prosthetic vessels [65, 66, 67, 68, 69, 70]. Moreover, there are
a number of SCVL systems developed to simulate some specific physiological
parameters of a native cardiovascular system [71, 72, 73, 74, 75, 76]. In a re-
cent study a hybrid (numerical-experimental) model of the native cardiovascular
system has been developed to overcome the problem of inflexibility in SCVL sys-
tems [59, 77]. SCVL systems can be classified into various categories in terms of
the number of chambers, type of actuators, type of heart valves, type of resis-
tance and compliance components, control techniques, measurement devices and
objectives. In this study, SCVL systems are classified into three main categories
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based on the number of actuators implemented to simulate the heart chambers:
• Single-Chamber SCVL
• Twin-Chamber SCVL
• Multi-Chamber SCVL
If the left ventricle and aorta are under investigation, the system has only one
chamber which is the left ventricle, one drive to excite the chamber and one or
two valves. If the systemic or the pulmonary circulation needs to be replicated,
two chambers, two drives and two or three valves are required. In the case of
recreating a complete circulation loop consisting of the systemic and pulmonary
loops, four chambers, four drives and four or five valves need to be employed.
1.6.1 Single-Chamber SCVL
The simplest SCVL system includes one chamber normally activated by a pneu-
matic or DC motor actuator. The objective of these devices would be, in general,
to evaluate the performance of newly developed time-varying elastance models
simulating dynamic mechanism of the heart. This type of SCVL system is easy
to set up and is also cost effective.
Colacino et al. [78] developed a single-chamber SCVL for simulation of the
left ventricle of the heart as shown in Figure 1.18. For the experimental model
a screw-driven piston cylinder mechanism actuated by a DC motor is employed
to drive the left ventricle chamber. In this model, the modified version of the
classical Suga-Sagawa elastance model [79] was employed to simulate the correct
ventricular pressure-volume relationship.
The experimental results show that the modified elastance function is able
to successfully reproduce the elastance mechanism of the native left ventricle
according to the Frank-Starling law [80]. However, as shown in Figure 1.19, the
Left Ventricle Pressure (LVP) waveforms in controlled and diseased conditions
1 Introduction 38
Figure 1.18: The photograph of the single-chamber SCVL system. From F. M. Colacino
et al. [78], A modified elastance model to control mock ventricles in real-time: Numerical and
experimental validation, 2008.
Figure 1.19: The LVP waveform for the diseased condition when the afterload pressure
increases and decreases, respectively from the SCVL system. From F. M. Colacino et al. [78],
A modified elastance model to control mock ventricles in real-time: Numerical and experimental
validation, 2008.
are not in close agreement with the left ventricle conceptual feature [80]. The
inherent rigidity of the tubing system combined with the DC motor vibration
results in significant transient oscillations appearing on the left ventricle pressure
waveforms and hence reduces the accuracy of the results.
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In another study, a hybrid one-chamber SCVL system was proposed by Ferrari
et al. [81] to reproduce the Frank-Starling law of the left ventricle using another
newly developed variable elastance function developed by the same team. In gen-
eral, a hybrid model combines the numerical model and the experimental model.
Therefore, a hybrid model shows better flexibility and performance compared to
a purely numerical or an experimental model. In a hybrid model, both numeri-
cal and experimental models are connected together through an electro-hydraulic
interface. This study employs an electro-hydraulic actuator. Depending on the
objective of the experiment, some part of the test can be implemented hydrauli-
cally and the rest numerically. Considering the electro-hydraulic analogy, the
hydraulic parameters including the pressure and the flow-rate are converted to
numerical parameters of the voltage and the current respectively. Figure 1.20
corresponds to the measured Aortic Pressure (AoP) from the test rig and the
computed LVP from the numerical model in a control condition, pathologic con-
dition and IABP assistance condition. Both numerical and experimental pressure
waveforms are within the physiologic levels. However, it can be observed that
the pressure waveform features are not predicted clearly.
Figure 1.20: The numerical LVP and experimental AoP waveforms from the SCVL sys-
tem. From G. Ferrari et al. [81], A hybrid mock circulatory system: Testing a prototype under
physiologic and pathological conditions, 2002.
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1.6.2 Twin-Chamber SCVL
In a twin-chamber SCVL, the ventricle is generally actuated by a pneumatic pump
and the atrium is simulated by an open-to-atmosphere water header tank. There-
fore, the atrium pressure is simulated by the constant static pressure from the
head of water in the tank throughout the cardiac cycle. To reproduce the systemic
or the pulmonary circulation in a twin-chamber SCVL system, a combination of
resistance and compliance components similar to the Windkessel model [82] have
been employed in previous studies [78, 81, 83].
Garcia et al. [84] describes a twin-chamber SCVL including the left ventricle,
left atrium and the systemic circulation. The objective of this study was to in-
vestigate the effect of the aortic valve abnormality on the hemodynamic response
of a left-side VAD device. As shown in Figure 1.21(a), the left ventricle chamber
was made of silicon rubber which is embedded inside the pressurised water tank.
The level of water pressure in the tank is controlled by the pump connected to
a stepper motor and it is driven according to the ventricular volume change.
The left atrium is simulated by an open-to-atmosphere water header tank. The
systemic compliance unit is simulated by a pressurized air tank. The total pe-
ripheral resistance is modelled with a single metal clamp. Both the mitral and
the aortic valves are modelled with two tricuspid bio-prosthetic valves. In this
study, the left ventricle pressure as well as the aortic pressure were measured at
four different levels of VAD support. Experimental results show that the twin-
chamber SCVL in this study can provide a reasonably controlled environment
for testing the characteristics of VADs. Figure 1.21(b) shows that both the left
ventricle and the aortic pressure waveforms are in a good agreement with the
clinical data [80]. However it is evident that due to the high level of transient
pressure oscillation, the main features of pressure waveforms are not predicted
clearly. This can be due to the inherent rigidity of the tubing system employed
for the systemic circulation. Another drawback of this SCVL is that the left
ventricle is not following the Frank-Starling law precisely in response to various
levels of pre-load and after-load changes. This can be justified as a result of not
using a more precise actuator for the left ventricle and using an inappropriate
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variable-elastance model for the left ventricle.
(a) (b)
Figure 1.21: (a) Schematic diagram of the twine-chamber SCVL system. (b) The LVP and
AoP waveforms for the diseased condition, From: M. A. Z. Garcia et al. [84], The effect of
aortic valve incompetence on the hemodynamics of a continuous flow, ventricular assist device
in a mock circulation, 2008.
In another study by Legendre et al. [85], a twin-chamber SCVL, as shown in
Figure 1.6.2(a), was developed to study the hemodynamic parameters of the left
ventricle and the aortic artery in various physiological and pathological condi-
tions. In this study, the left ventricle displacement is modeled through a di-
aphragm actuated by a piston. A connecting rod is used to convert the linear
displacement of the piston into the rotary motion of a DC motor. The left
atrium is modeled by an open to atmosphere tank. Alternation of the height of
the atrium tank results in a change of pressure inside the left ventricle. This leads
to a simulation of various physiological or pathological conditions in the system.
In addition to the pressure and the flow-rate, in this study, the temperature was
being measured constantly and kept stable, very close to the physiological tem-
perature of a native body. To simulate the characteristics of natural blood, a
mixture of 63% water and 37% glycerol was used as the working fluid [85].
Figure 1.6.2(b) shows the aortic pressure and the corresponding flow waveform
in a control condition. It is evident that the measured aortic pressure waveform
is in good agreement with the clinical data [80]. However the main features of a
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pressure waveform such as dicrotic notch, appearing normally in the clinical aortic
pressure, was not predicted clearly. Another drawback of this system is that due
to the use of the DC motor as an actuator of the left ventricle, the left ventricle
chamber is getting activated at a fixed rate. Therefore, the cardiac iso-volumetric
phases cannot be predicted precisely. This is similar to the study conducted by
Colacino et al. [78]. It is concluded that the DC motor as an actuator is not an
appropriate option to actuate the left ventricle.
(a) (b)
Figure 1.22: (a) Photograph of the twin-chamber SCVL system, (b) Control panel shows the
AoP and aortic flow waveform for the controlled condition. From: D. Legendre, et al. [85], Mock
circulatory system for the evaluation of left ventricular assist devices, endoluminal prostheses,
and vascular diseases, 2008.
Another study on a twin-chamber SCVL was conducted by Sharp et al. [86].
The objective of this SCVL was to simulate the Frank-Starling response of a
native body in different physiological and pathological conditions. The test rig
simulates the systemic circulation and includes two chambers of the left atrium
and the left ventricle. The left atrium chamber is made of a flexible polymer
and the left ventricle chamber is made of a polymer sac embedded inside another
pressurized chamber. The required air for compressing the ventricular chamber
during the systolic phase to deliver the cardiac stroke volume is provided by a
pneumatic actuator connected to a control system. The mitral valve is modeled by
polyurethane trileaflet valve and the aortic valve is modeled by a rigid tilting disk.
Figure 1.23 shows the schematic diagram of the SCVL system developed by Sharp
et al. [86]. The compliance unit in this system was modelled by using a coil spring-
loaded bellows and the resistance unit was modeled by using a compressible folded
fibre-sheet. The whole vasculature system is connected through tygon tubing. To
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control the effect of impedance on the system, the tubing system length has been
optimised and the input impedance of the system has been measured in terms of
different levels of resistance and compliance units.
Figure 1.23: Schematic diagram of the twin-chamber SCVL. From M. K. Sharp et al. [86],
The influence of mock circulation input impedance on valve acceleration during in-vitro cardiac
device testing, 2008.
Figure 1.24 shows the AoP and LVP waveforms for a controlled condition.
Final results show that the SCVL system was able to reproduce the Frank-Starling
response reported clinically and the simulated native pressure and flow waveforms
were in good agreement with the native system. It is evident from Figure 1.24
that the main features of the aortic pressure waveforms include a sharp rise of
the systolic pressure, gradual fall of the diastolic pressure and the dicrotic notch,
which are predicted fairly similar to the clinical data. In comparison with the
other studies [78, 84, 85] on twine-chamber SCVL systems, it is evident that the
measured pressure trace carries the least transient oscillations which is mainly
due to the use of an appropriate compliance unit.
Studies such as [78, 84, 85, 86, 87] on twin-chambers SCVL systems show that
these emulators are able to replicate the action of a native system at various phys-
iological and pathological conditions. However, they have inherent limitations in
emulating the atrium-to-ventricle and the ventricle-to-artery interactions of both
the systemic as well as pulmonary circulations. Moreover, the hemodynamic
assessment of bi-VADs or the effect of the left-side VADs on the pulmonary cir-
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Figure 1.24: The experimental AoP and LVP for the controlled condition from the SCVL
system. From M. K. Sharp et al. [86], The influence of mock circulation input impedance on
valve acceleration during in-vitro cardiac device testing, 2008.
culation is required to have additional features. In order to investigate the central
and peripheral hemodynamic variables of the systemic and the pulmonary circu-
lations simultaneously, a cardiovascular simulator needs more additional features.
Therefore, there is a need for the development of a cardiovascular simulator which
behaves similar to a native cardiovascular system.
1.6.3 Multi-Chamber SCVL
Multi-chamber SCVL systems consist of four chambers including two ventricles
and two atriums. In previous studies [78, 81, 83], the ventricle chambers were
generally actuated by pneumatic pumps and the atriums were simulated by two
open-to-atmosphere water header tanks. To reproduce the systemic as well as
the pulmonary circulation in a multi-chamber SCVL, a combination of resistance,
compliance and up to five mechanical or biological valves were used.
Timms et al. [83] developed a multi-chamber SCVL system to evaluate the
effect of left-side VAD, right-side VAD or both on the systemic as well as the
pulmonary circulation. The test rig includes four chambers of the heart. The
right and the left ventricle chambers were controlled by two pneumatic actua-
tors. The contraction and expansion of the ventricle chambers are controlled
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by compressing and ventilating air through a 3/2˝ solenoid valve into the corre-
sponding chambers using a regulated compressor. Two air/water header tanks
for each of the atriums were employed as shown in Figure 1.25. Any change in the
volume of water in the atriums determines the pre-load pressure in the ventricle
chambers. The pathological conditions were modelled by changing a number of
vasculature parameter characteristics, such as mean circulatory pressure, heart
rate, ventricle elasticity, systemic and pulmonary resistances and compliance.
Figure 1.26 shows that the measured left ventricle and the aortic pressures are in
Figure 1.25: Schematic diagram of the multi-chamber SCVL system. From: D. Timms et
al. [83], A complete mock circulation loop for the evaluation of left, right, and biventricular
assist devices, 2005.
good agreement with the clinical data [80]. The results show that the test rig is
thoroughly adherent to the Frank-Starling law, however due to the inherent rigid
nature of the vasculature system and rapid closure of the swing check valves,
the pressure waveforms carry significant transient pressure oscillations. As a re-
sult, similar to previous studies [78, 85], some features of the clinical pressure
waveform, such as dicrotic notch appearing on the aortic pressure waveform were
not predicted. In addition, it is evident from Figure 1.26 that there is a phase
difference between the aortic pressure and the left ventricle pressure which can
be attributed to the inherent rigidity of the vasculature system and the use of an
inappropriate compliance unit in the system.
Figure 1.28 shows another multi-chamber SCVL system developed by Panta-
los et al. [88]. The objective of the system was to investigate the hemodynamic
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Figure 1.26: LVP and AoP waveform for a controlled condition from the SCVL system. From:
D. Timms et al. [83], A complete mock circulation loop for the evaluation of left, right, and
biventricular assist devices, 2005.
response of a pediatric cardiovascular system in the presence of a pediatric car-
diopulmonary assistance device. In this study, the ventricles are made of polymer
sac embedded inside pressurised chambers. Each chamber was actuated individ-
ually by a separate pneumatic pump. The atriums were made of silicon rubber.
The polyvinyl tubing with an inner diameter of 3/8˝ were incorporated to mimick
the systemic as well as the pulmonary vasculature. A number of pinch clamps
were used to control the pulmonary and the systemic resistances. The systemic
and pulmonary compliances are modelled using the latex tubing. The results
show that the SCVL system is capable of mimicking the hemodymamic pressures
and flows reasonably close to a native pediatric system. However, similar to
previous studies [78, 83, 85], the system is not capable of predicting the crucial
features of the clinical pressure waveforms. For instance, comparison of the mea-
sured aortic pressure and the corresponding clinical data in Figure 1.28 indicates
that the sharp rise of the aortic pressure waveform during the systolic phase is
not close to the corresponding clinical waveform. It is apparent that the use
of a pneumatic driver to actuate the ventricles is not an accurate technique to
simulate full phases of cardiac function.
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Figure 1.27: Photograph of the pediatric multi-chamber SCVL system. From: G. M. Pana-
talos et al. [88], Expanded pediatric cardiovascular simulator for research and training, 2010.
Figure 1.28: Comparison of the clinical and the experimental AoP for a controlled condition
from the SCVL system. From: G. M. Panatalos et al. [88], Expanded pediatric cardiovascular
simulator for research and training, 2010.
Another multi-chamber SCVL system was developed by Liu et al. [89] to in-
vestigate the hemodynamic response of the cardiovascular system to a left-side
VAD. As shown in Figure 1.29, the ventricles are modelled by two silicon di-
aphragms which were embedded inside the corresponding pressurized air cham-
bers. The expansion and the contraction of each of the chambers were controlled
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by a pneumatic system. Air/water header tanks were used to model the venous
chamber, the artiums and the pulmonary compliance. Clear tygon tubes were
used to model the vasculature circulation and a number of tuning clamps were
used to control the systemic and pulmonary resistances.
Figure 1.29: Schematic diagram of the multi-chamber SCVL system. From: Y. Liu et al. [89],
Mechanical simulator of the cardiovascular system, 2009.
Figure 1.30: Experimental LVP and AoP for a diseased condition measured from the SCVL
system. From: Y. Liu et al. [89], Mechanical simulator of the cardiovascular system, 2009.
Figure 1.30 shows that although the aortic and the left ventricle pressure are
in reasonable agreement with the clinical data, similar to previous studies [78,
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83, 85, 88], the SCVL system cannot predict the crucial feature of the clinical
pressure waveform. Moreover, due to the limited displacement of the diaphragm
in the ventricle chambers, the system has not adhered to the Frank-Starling law
of the native heart. Thus, the system’ response to the left-side VAD device is not
reliable.
In a nutshell, the results from previous studies [78, 83, 85, 88, 89] show that
although the measured hemodynamic findings from SCVL systems are in rea-
sonable agreement with the clinical data, these cardiovascular emulators cannot
predict the crucial clinical features as found in a native cardiovascular system.
For instance, due to the inherent rigidity of the tubing system and the use of in-
appropriate compliance units, the original measured pressure waveforms carried
significant levels of transient oscillations [83, 88]. Therefore, some features of the
clinical aortic pressure waveforms such as the dicrotic notch were not captured.
Further, it was observed that the implementation of the conventional pneumatic
driver to actuate the ventricles produces better results compared to the use of a
DC motor. However, the application of a pneumatic actuator has a drawback.
For simulating the diastolic phase, the solenoid valve needs to be vented to the
atmosphere resulting in an immediate vacuum. Therefore, the rapid and slow
filling phases of the native system are not simulated properly. Another draw-
back of the previous SCVL systems is the lack of a full simulation of the atriums
instantaneous activation function. In all previous studies [83, 88, 89, 90] includ-
ing single-chamber, twin-chamber and multi-chamber SCVL systems, the atrium
chambers are represented by an open to atmosphere header tank. Changing the
height of the tank leads to a change of pre-load pressure in the ventricle cham-
bers. However, in an intact heart, the atrium muscles are active and the pressure
inside the atrium is not constant and varies instantaneously.
Considering the deficiencies of the existing SCVL systems, there has been a
need to develop a multi-chamber SCVL system fully capable of simulating the
hemodynamic features of a native cardiovascular system in different physiological
and pathological conditions. The new cardiovascular simulator should replicate
the whole cardiovascular system including the heart and the systemic as well as
the pulmonic circulations. To avoid hemodynamic complications, as indicated in
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the existing SCVL systems, an appropriate compliance unit for both the systemic
as well as the pulmonary circulation needs to be incorporated. In addition, new
sets of actuators which are able to model all four phases in one cardiac cycle need
to be employed.
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1.7 Aims and Objectives
It is demonstrated that the descending aorta can be a promising location to install
a long-term implantable MCS device with minimally invasive surgery. However
there is a theoretical concern that as the pump is operating in the descending
aorta, there may be a steal phenomenon of blood from the brain and the upper
extremities. In addition, there is a question associated with the effect of the
pressure rise on renal perfusion.
The aim of this thesis is to conduct numerical and experimental investigations
on the hemodynamics responses of the cardiovascular system aided with an MCS
device operating in the descending aorta. The numerical and experimental sim-
ulations of the cardiovascular system allow investigation into the hemodynamic
parameters of the whole circulatory system which is not feasible in a native human
body due to the complexity of the system.
The objectives of this study are met by using our in-house multi-chamber SCVL
system as well as the Concentrated Lumped Parameter (CLP) model developed
by our team. In each case, different pathological conditions were simulated nu-
merically as well as experimentally according to the clinical data.
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1.8 Outline of the Thesis
A brief outline of the thesis is presented below.
Chapter 2 evaluates the performance of the multi-chamber SCVL system
by simulating three physiological and pathological conditions; control, conges-
tive heart failure (CHF) and left ventricular diastolic disfunction in hypertension
(LVDDH). Using four tubular permanent magnet linear motors and working ac-
cording to the prescribed elastance function of the native ventricles and atria
shows the high success of this technique in emulating the contraction phase fill-
ing phases as found in the native cardiac muscle. In addition, in this chapter two
rotary pumps, pump A and B, are introduced and the characteristics of each are
evaluated at various rotor speeds.
Chapter 3 presents an experimental investigation on the novel approach of
placement of the pump in the descending aorta, in-series with the heart, and its
comparison with the traditional approaches of the Left Ventricle to Ascending
Aorta (LV-AA) and the Left Ventricle to Descending Aorta (LV-DA), in-parallel
with the heart. Tests were conducted by using the in-house multi-chamber SCVL
system. The results indicate that the use of in-parallel LV-AA configuration leads
to a significant improvement in the systemic and the pulmonic flow as the level
of continuous flow is increased. The use of LV-DA in-parallel technique leads to
an improvement in the systemic and pulmonic flow at lower level of continuous
flow but at higher level of support leads to a flow retrogradation. In both in-
parallel approaches (LV-AA and LV-DA), increasing the level of MCS continuous
flow leads to a decrease in the aortic and the carotid pulse pressures to a certain
extent. The results of the in-series configuration show that the pressure drop
upstream of the pump facilitates the cardiac output as a result of the after-load
reduction. Also the pressure rise downstream of the pump may assist with the
renal perfusion. At the same time the generated pressure drop at the proximal
part of the descending aorta induces a slight drop in the carotid perfusion which
will be autoregulated by the brain in a native cardiovascular system. The pulse
wave analysis show that the placement of the pump in the descending aorta, in
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series with the heart, leads to improved pulsatility which is beneficial for end-
organ functionality in the native cardiovascular system.
Chapter 4 presents a comprehensive numerical and experimental study on the
novel approach of placement of the pump in the descending aorta, in-series with
the heart, using the modified concentrated lumped parameter (CLP) model as
well as the multi-chamber SCVL system respectively. The numerical results are
compared and verified by experimental results under various conditions. Both
experimental and numerical studies show that the generated pressure gradient in
the descending aorta can lead to an increase in cardiac output and abdominal
organs perfusion (e.g. liver, kidneys). Also, it causes a substantial improvement
in the flow and pressure pulsatility. However, at the same time, depending on
the level of pump support, it induces a slight drop in carotid perfusion, whom in
a native cardiovascular system may be compensated through the auto-regulation
system of the brain.
Chapter 2
Design and Development of Simulator of the
Cardio-Vascular Blood-Flow Loop
2.1 Motivation
The design and development of a mechanical cardiovascular system simulator is
motivated by the necessity and significance of in-vitro tests of various artificial
devices such as heart valves, ventricular assist devices (VAD), mechanical circu-
latory support (MCS) devices etc. In order to model the whole cardiovascular
system correctly, the characteristics of each part of the system should be mod-
elled accurately. Although, it is practically impossible to accurately model every
part of the cardiovascular system with in-vitro models, an approximate model in
which all the key flow elements are represented is achievable.
The Simulator of cardiovascular loops (SCVL) systems are classified into three
main categories based on the number of actuators implemented to simulate the
heart chambers; single-chamber SCVL, twin-chamber SCVL and multi-chamber
SCVL. The simplest SCVL system includes one chamber normally activated by
a pneumatic actuator. This is easy to set up and cost effective. The objective
of these devices would be, in general, to simulate the pressure-volume relation
of the native heart [91, 92, 93, 94, 95, 96]. For instance Colacino et al. [78] and
Ferrari et al. [81] separately developed a single-chamber SCVL system to emulate
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ventricular function. The results show that single-chamber SCVL systems are
able to successfully reproduce the time varying elastance of the native ventricle,
thus achieving a good representation of Frank Starling’s law of the heart, but
they have limitations in reproducing the effects of pulmonary circulation in the
system.
In a twin-chamber SCVL system the ventricle is normally actuated by a pneu-
matic pump and the atrium is simulated by an open-to-atmosphere water header
tank which simulates the atrial pressure by the constant pressure from the head
of water in the tank throughout the cardiac cycle. Two heart chambers (i.e. one
atrium and one ventricle, or two ventricles), with two actuators, and up to three
heart valves in addition to the resistances (R) and compliances (C) inherent to
the system are required to closely emulate additional aspects of the circulation
loops. For instance Garcia et al. [84] describes a twin-chamber SCVL system to
investigate the effect of opening and closing the aortic valve on the hemodynamic
response to the continuous flow produced by a left-side VAD. Other work con-
ducted by Sharp et al. [86] describes a twin-chamber SCVL to study the effect
of arterial impedance on the closing dynamics of prosthetic heart valves. These
devices have good ability to replicate the action of the native system at physiolog-
ical and pathological conditions, but they have inherent limitations in emulating
the atrium-to-ventricle and ventricle-to-artery interactions of both systemic and
pulmonary circulations. In order to investigate the central and peripheral hemo-
dynamic variables of the systemic and pulmonary circulations simultaneously
SCVLs need additional features.
The increasing number of patients using VADs and MCS devices requires more
elaborate methods to study the hemodynamic impact of these devices (for in-
stance to simulate the effect of the addition of continuous flow devices on the
resultant overall pulsatile flow from the combination of the native heart and
VAD/MCS).
In general a multi-chamber SCVL consists of four chambers of the heart, both
systemic and pulmonary circulations, and up to five mechanical or biological
valves. The results for all previous studies on multi-chambers represent accurately
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diastolic and systolic pressure and flow rate; however, the features of the pressure
waveform are not well captured, particularly at the interface between the cardiac
chamber and the valve where there seems to be a large pressure gradient across
the valve [83, 88, 90, 97]. Another aspect of multi-chambers SCVL system,
which has not been appropriately addressed, is the simulation of the full atrial
instantaneous activation function, particularly the representation of the filling
phase of the chamber [83, 88, 89, 90]. One of the purposes of this SCVL system
is to simulate the arterial pressure waveforms, closer to a control condition as that
found in the clinical setting, including a steep rise of the pulse pressure, dicrotic
notch which is due to the closure of the aortic valve, and a gradual decline of
pressure to the end-aortic diastolic pressure.
This chapter evaluates the performance of the multi-chamber SCVL system
by simulating three physiological and pathological conditions; control, conges-
tive heart failure (CHF) and left ventricular diastolic disfunction in hypertension
(LVDDH). The experimental measurements are compared with the numerical
data obtained with adaptations of programs described in different studies con-
ducted by Korakianitis et al. [98, 99, 100, 101, 102, 103], where in addition to
the previous work, we have added the upper limb and the lower limb segments.
A comprehensive description of the modified numerical model will be presented
in Chapter 4.
It is worth mentioning that Dr. Akbar Rahideh and Dr. Paula Ruiz have a had
a significant collaboration in development of the multi-chamber SCVL system.
2.2 Methodology
Figure 2.1 and Figure 2.2 show a photograph and schematic representation of the
multi-chamber SCVL system respectively. The multi-chamber SCVL system can
be classified into three main parts:
• Heart model
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Figure 2.1: Photograph of the multi-chamber SCVL test-rig, LM: Linear Motor, LA: Left Atrium, LV: Left Ventricle, RA: Right
Atrium, RV: Right Ventricle, C: Compliance, F: Flow meter.
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Figure 2.2: Schematic diagram of the SCVL system.
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• Pulmonary and systemic circulations
• Control, measurement and monitoring systems
The heart model consists of four chambers, four actuators and four heart valves.
2.2.1 Chambers
The SCVL system consists of four chambers each representing an individual
chamber of the native heart. Figure 2.4 shows the photograph of the left ventricle
chamber. The left ventricle chamber was designed and manufactured separately
based on the diaphragm pump mechanism with an internal size of 200 ml. The
chamber consists of an acrylic cylinder and the inner diaphragm disk made of
elastic rubber, as shown in Figures 2.3. The diaphragm disk is connected to a
linear motor. Changing the position of the linear motor, according to the time
varying elastance function of the left ventricle, leads to a change in position of
the diaphragm inside the chamber.
Figure 2.3: Schematic diagram of the left ventricle chamber.
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Figure 2.4: Photograph of the left ventricle chamber.
For modeling three other chambers, including the right ventricle, right atrium
and left atrium, three rubber gaiters with proper sizes ( right ventricle with a
volume of 120 ml; left atrium and right atrium with a volume of 50 ml) are used to
represent the three native heart chambers, as shown in Figure 2.5. Each rubber
gaiter is connected to an individual linear motor. Driving each rubber gaiter
back and forth, according to the corresponding time varying elastance function,
simulates the diastolic and systolic phases of the native heart chambers.
Figure 2.5: Photograph of the right atrium chamber.
2.2.2 Actuators
In previous studies, stepper motors [97] or pneumatic actuators [83, 88, 89, 90]
have been used to actuate the heart chambers. Stepper motors are not the obvious
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choice when a system is required to emulate pathophysiological conditions as there
would be a need to change the mechanism.
Conventional pneumatic actuators accurately simulate the contraction phase of
the cardiac muscle by injecting compressed air into a flexible membrane. A down-
side of the pneumatic actuator is that for simulating the diastole, the solenoid
valve needs to be vented to atmosphere resulting in an immediate vacuum; conse-
quently, the rapid and slow filling phases of the native system are not simulated.
Figure 2.6: Schematic representation of the linear motor.
In our study four identical tubular permanent magnet linear motors (P01-
37x120 from LinMot, Switzerland) have been employed to drive the four chambers
of the heart. As shown in Figure 2.6, each linear motor consists of a cylindrical
slider which moves linearly inside a stator. The maximum stroke displacement is
1460 mm. Each linear motor produces the peak force of 163 N with a maximum
velocity of 3.2 m/s.
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2.2.3 Heart Valves
A heart valve is a unidirectional valve which operates on the basis of the pressure
difference on either side of the valve. The best option for heart valves to be
used in SCVL systems is off-the-shelf artificial heart valves. Two main types of
artificial heart valves are the mechanical and biological valves. The mechanical
valves are divided further into ball and cage valves, tilting disc valves, bi-leaflet
valves and polymeric valves. The mechanical valves are stronger and more fault
tolerant than biological valves. The drawback of mechanical valves is that their
inflexible structure may cause some unwanted hemodynamic oscillations [46].
Biological valves normally consist of two or three leaflets made of animal tis-
sues. Similar to natural valves in a native body, the opening-closing mechanism
of biological valves is based on the pressure gradient across the valves. If the
upstream pressure is greater than the downstream pressure, leaflets are pushed
outward to let the flow pass whereas if the downstream pressure is greater than
the upstream pressure then the leaflets overlap in the center and do not allow
the retrograde flow. Biological valves show better functionality compared to me-
chanical valves and they cause less biological complications such as thrombology.
However they are more expensive and their long-term durability is lower than
the mechanical valves [104]. Figure 2.7 (a-b) show two types of off-the-shelf
mechanical valves and biological valves respectively.
In previous studies on SCVL systems, both the mechanical and the biologi-
cal valves have been employed. For instance, Timms et al. [83] implemented a
couple of swing check valves to simulate the four heart valves. In another study
conducted by Sharp et al. [86], the mitral valve was modeled by a polyurethane
tri-leaflet valve and the aortic valve was modeled by a rigid tilting disk. Hemo-
dynamic results showed significant transient oscillations on the pressure and flow
traces. This is regarded as the hammer effect and it is due to the sudden opening-
closing mechanism of the rigid tilting disk. In another study conducted by Garcia
et al. [84] both the mitral and the aortic valves are modeled with two tricuspid
porcine-bio-prosthetic valves. Hemodynamic results showed less transient har-
monic effects on the pressure and flow waveforms.
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Figure 2.7: Photograph of (a) Mechanical valve, (b) Biological valve. From: H. Moham-
madi [104], Prosthetic aortic heart valves: Modeling and design, 2011.
In our study as illustrated in Figure 2.2, four tilting disc heart valves cor-
responding to the mitral, pulmonary, tricuspid and the aortic valve have been
used in the vicinity of each chamber to control the unidirectional flow. In addi-
tion, another mechanical valve is set at the end of the vena cava before the right
atrium to help venous return and prevent backflow of blood. These five mechani-
cal heart valves are Medtronic’s 29 mm diameter Hall Easy-Fit mechanical valves
(Minneapolis, Minnesota, USA).
2.2.4 Resistance Units
Vascular resistance is the key factor to control the blood perfusion in different
parts of a native cardiovascular system. The level of resistance in each local
vessel is variable. The resistance level in any local vessel changes inversely with
the flow rate. In large arteries, due to the low level of resistance, the pressure
drop is small, whereas in arterioles and terminal arteries, due to the high level
of resistance, the pressure drop is more pronounced [1]. Variable resistances can
be introduced into a mock cardiovascular system to mimic different conditions
and diseases. Two major concepts for introducing resistances into the system
is to implement the proportional multi-turn pinch or globe valves which can be
controlled manually or automatically using stepper motors.
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(a) (b) 
Figure 2.8: (a) Globe resistance, (b) Pinch resistance.
In the study by Timms et al. [83], the vascular resistance of arteries, capillaries
and veins of the systemic as well as the pulmonic circulations were combined into
two lumped resistance units using two control pinch valves which are adjusted
by the input voltage. In the studies by Colacino et al. [78] and Legendre et
al. [85], a screw clamp was placed in the aorta to change the ventricular after-
load pressure for different pathological conditions. The after-load pressure can
be increased or decreased by tightening or loosening of the resistance. In another
study by Pantalos et al. [88], the total systemic as well as pulmonary resistance
were modelled using a tuning clamp and a gate valve respectively.
In our study total systemic and pulmonary resistances have been modelled by
using a set of adjustable resistors (Hoffman clips screw-type occluder). Figure 2.9
shows a photograph of the Hoffman clips. The resistance level can be increased or
decreased by tightening or loosening of the screw. As it is evident in Figure 2.2,
a set of clips have been distributed proportionally in different parts of the SCVL
system. The level of resistance at various parts of the systemic and pulmonary
loops has been manually adjusted to mimic different pathological states.
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Figure 2.9: Hoffman clips resistances.
2.2.5 Compliance Units
One of the most influential characteristics of an SCVL system is the compliance
unit. The compliance unit should preferably be adjustable to provide the opportu-
nity to mimic different conditions and diseases. In prior studies [83, 85, 87, 88, 89],
to simulate the compliance of a native vascular system, different ideas have been
implemented.
A simple idea is to use a highly compliant balloon placed in a bucket of water,
as shown in Figure 2.10(a). Any change in the level of water in the bucket changes
the compliance level. Another concept, as shown in Figure 2.10(b), is a cylinder
and piston concept. In this concept, the piston is connected to a fixed plate
through a number of springs. Use of a different spring constant or a change in
the number of springs changes the compliance level. The latter concept which
has been employed in this investigation, as shown in Figure 2.10(c), consists of a
chamber partially filled with liquid, with compressed air above the water column.
Any change in air pressure results in a change in the compliance level.
Timms et al. [83] have employed a couple of tunable pressurised air-water
chambers. In the other studies conducted by Pantalos et al. [88] and Legendre
et al. [85], both the systemic and venous compliances have been modelled by a
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Figure 2.10: (a) balloon and bucket concept, (b) piston and cylinder concept, and (c) pres-
surized air-water concept.
piston cylinder mechanism loaded through a spring. Liu et al. [89] have employed
three pressurised air tanks for simulating the systemic as well as pulmonary com-
pliances. The level of air pressure inside each tank is adjusted by a valve provided
on the top and it is measured by a pressure gage.
Figure 2.11: Photograph of the air/water compliance unit connected to a latex balloon.
In our study two different compliance units have been employed:
• Air/water compliance
• Rubber-bellows compliance
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The air/water compliance units have been modelled by using four air capacitors
which consist of a chamber partially filled with both water and compressed air,
with one located in the ascending aorta, one in the pulmonary circulation, and two
in the vena cava artery, as shown in Figure 2.2. The level of air pressure in each
compliance has been adjusted via a sphygmomanometer for various physiological
conditions. Any change in air pressure changes the level of compliance in the
system. In order to increase the compliance characteristics of each unit, a latex
balloon with particular specifications has been connected to each compliance unit,
as shown in Figure 2.11.
In addition, due to the importance of the sinus aortic artery compliant charac-
teristics, in various physiological and pathological conditions, in a native cardio-
vascular system, an individual compliance unit has been added to the ascending
aorta. This compliance unit, as shown in Figure 2.12 has different specifica-
tions than the compressed air/water tank units. It consists of a rubber-bellow
unit which is adjustable through a knob. Turning the knob clockwise and anti-
clockwise results in various levels of compliance into the system.
2.2.6 Systemic and Pulmonic Circulation
The model of the systemic and pulmonic vasculature was conducted with the
intention of accurately distributing the cardiac output to the upper body, lower
body and the heart. The replicated systemic and pulmonary vasculature are
presented in Figure 2.2.
The aortic artery and abdominal artery segments are made of glass and the rest
of the systemic and pulmonary vasculature are reproduced using 24 mm diameter
rubber tubing, according to the anatomical features similar to a study conducted
by Pantalos et al. [88].
Figure 2.2.6(a) and Figure 2.2.6(b) show the schematic diagrams of the aortic
artery segment and the abdominal artery segment respectively. The aortic artery
segment consists of the ascending aorta and its branches, right and left subclavian
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Figure 2.12: Schematic diagram of the rubber-bellow compliance.
arteries, right and left common carotid arteries and the brachiocephalic trunk.
The abdominal artery segment consists of the right and left renal arteries and
common iliac branches.
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Figure 2.13: (a) Schematic diagram of the aortic artery section, (b) Schematic diagram of
the abdominal artery section.
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2.2.7 Control System
A control system, integrated in an SCVL system, can either be open-loop or
closed-loop. Figure 2.14 shows the schematic diagram of the open-loop control
system. The open-loop control systems do not use the measured signals in the
control process and the desired trajectory signals to the actuators are predefined,
so there is no need for a sensor. The advantage of an open-loop system is that
it is low cost and easy to set up. However, in an open-loop system, producing
a desired signal is not an easy task and it can be done manually through a trial
and error process. Moreover,an open-loop control system cannot compensate for
any disturbance or fault in the system. Owing to the simplicity and low cost, the
open-loop control systems have been integrated into a number of prior studies on
SCVL systems [85, 86].
Linear 
motor
PC DAQ
Signal 
generator
Clinical 
data
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Plots
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oller
Figure 2.14: Schematic diagram of an open-loop control system.
Figure 2.15 shows the schematic diagram of the closed-loop system. In a closed-
loop control system, the measured signals are fed back to the controller to change
the desired trajectory signals based upon the instantaneous error between the
desired and the measured signals. Sensors are necessary compartments of the
closed-loop-control system. A closed-loop proportional-integral control system is
more accurate, complex and expensive than the open-loop control system but
it performs well for a multi-variable system. However the drawback of using
a closed loop system for a multi variable system is that if one of the variables
are not well-tuned, due to the disturbances in feedback signals, the system may
become unstable.
Colacino et al. [78] employed the closed-loop system to control the displacement
of the left ventricle actuator. In their study, the left ventricle pressure is chosen
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Figure 2.15: Closed-loop control system diagram.
as a control variable. So, in each cardiac cycle the pressure inside the ventricular
chamber is measured by a pressure transducer and is fed back to the controller.
The actuator displacement is adjusted in accordance with instantaneous error
between the desired and real measured pressure signals.
In our study, due to the simplicity and low cost, the open-loop control system
has been integrated into our multi-chamber SCVL system. Figure 2.16 shows
the schematic diagram of the open-loop control system employed in the multi-
chamber SCVL system. To control the position of the motors, a controller (E400
from LinMot, Switzerland) with 4 control channels is employed which is able to
accurately and independently control the displacement of each slider according
to a predefined time-varying function as shown in Figure 2.17.
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Figure 2.16: Schematic diagram of the open-loop control system, employed in the multi-
chamber SCVL system.
A high speed, high performance Data AcQuisition card (DAQ) with four ana-
logue outputs, 16 analogue inputs and 48 digital input/outputs (NI PXIe-6368
from National Instrument, Hungary) has been used. DAQ sends the desired
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displacement trajectories from the PC to the linear motor controller as well as
it reading the measurement signals from the pressure transducers and the flow
meter into the PC.
Figure 2.17: Photograph of the DAQ card and the linear motors controller.
The desired trajectory generation and monitoring tasks have been achieved us-
ing the NI LabView program. Figure 2.18 shows the NI LabView program on the
computer screen monitoring the measured signals in red and desired trajectories
in green. The upper panel and the lower panel show the measured aortic pressure
waveform before and after tuning the SCVL system respectively.
Figure 2.18: Monitoring the measured signals and desired trajectories on computer screen
using NI LabView program.
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2.2.8 Time-Varying Elastance Function
The dynamic action of the heart is governed by the Frank-Starling law [80] which
can be functionalized in the ventricular and the atrial chambers in response to
the pre-load variation in order to simulate the physiological and pathological
conditions.
A wide number of variable elastance functions have been developed in order
to reproduce the Starling’s law of heart [91, 92, 93, 94]. Suga et al. [93, 94] in
1973 developed the first numerical elastance function of the left ventricle which
reproduces the Starling’s law of a native heart. They concluded that the pressure-
volume ratio (Elastance) is independent of the end-diastolic volume (pre-load) as
well as the arterial pressure (after-load) and hence could be used to character-
ize the ventricular contractility. The classical Suga-Sagawa model utilizes linear
relation between simultaneous intraventricular pressure and volume. Since then,
many researchers in various studies [78, 81, 95, 96, 105] have improved and op-
timised the classical Suga-Sagawa model to achieve closer agreement with the
complex and time-varying mechanism of the native heart in various physiological
and pathological conditions.
In our study, each linear motor slider is displaced, according to the well es-
tablished time-varying elastance model as used in different studies conducted by
Korakianitis et al. [98, 99, 100, 101, 102, 103] to individually activate the four
chambers. Considering the left ventricle for instance:
Dlv(t) = Dlvmin +
Dlvmax − Dlvmin
2
e(t) (2.1)
where Dlv(t) represents the time-varying displacement of the left ventricle linear
motor as a function of the maximum and minimum position of the slider (Dmax
and Dmin) and e(t) represents the activation function as adopted from studies
conducted by Korakianitis et al. [98, 99, 100, 101, 102, 103]. Equation (2.2)
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presents the activation function of the left ventricle in a single cardiac cycle:
elv(t) =


1− cos
(
t
Tvc
pi
)
: 0 ≤ t < Tvc
1 + cos
(
t− Tvc
Tvf − Tvc
pi
)
: Tvc ≤ t < Tvf
0 : Tvf ≤ t < T
(2.2)
where Tvc and Tvf are related to the time to reach the maximum contraction
and that to initiate chamber filling of the left ventricle respectively. The model for
the right ventricle is similar to that for the left atrium, apart from the parameters.
Equation (2.3) presents the activation function of the left atrium in a single
cardiac cycle:
ela(t) =


0 : 0 ≤ t < Tac
1− cos
(
t− Tac
Taf − Tac
2pi
)
: Tac ≤ t < Taf
0 : Taf ≤ t < T
(2.3)
where Tac and Taf are related to the time to reach the maximum contraction
and that to initiate chamber filling of the atrium respectively. The model for the
right atrium is similar to that for the left atrium, apart from the parameters.
The time parameters are listed in Table 2.1.
Table 2.1: List of time parameters.
Parameter Value Unit
HR 60 bpm
T 1.0 s
Tvc 0.3 s
Tvf 0.45 s
Tac 0.85 s
Taf 1.0 s
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2.2.9 Measurement Devices
Several measurement devices are employed to evaluate the performance of an
SCVL system as well as to provide necessary feedback signals in the case of closed-
loop control systems. Flow and pressure are the most important parameters
to be measured. The volume measurement, additionally, can assist to further
evaluate the performance of the test rig. The number of flow-meters, pressure
transducers and volume sensors employed depend on the application, accuracy
and the required outcome of the SCVL system.
Among various flow-meters such as nutating disk, oval gear, pressure-based,
optical, thermal mass, vortex, magnetic, coriolis, ultrasonic and laser doppler
flowmeters, the electro magnetic and the ultrasonic ones have been commonly
used. An electromagnetic flowmeter integrates a couple of magnetic poles on
either side of the flow stream. As semi-conductor flow cuts through the magnetic
field it produces electric potential which is proportional to the flow velocity. Then,
the diameter of the tube can be used to measure the flow rate [1]. In this study, as
shown in Figure 2.19(a), an electromagnetic flow meter of SITRANS F M MAG
1100 F from Siemens, Germany has been employed to measure the flow rate of
the ascending and the descending aorta.
Different pressure transducers are available including piezoresistive strain
gauge, capacitive, electromagnetic, piezoelectric and optical variations types.
The pressure transducers employed in the SCVL system should have the abil-
ity to measure the pressure in a range of 1-200 mmHg. This study employs a
couple of pressure transducers of PMP1400 Druck from General Electric Com-
pany, as shown in Figure 2.19(b), to simultaneously measure the pressures at the
key points in the system as shown in Figure 2.19(b). The operating pressure of
the PMP 1400 pressure transducer ranges from 0 to 250 mbar gauge. The supply
voltage ranges from 9 to 30V d.c. The output voltage ranges between 0 to 5V
and the operating temperature ranges from -200◦C to +800◦C.
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Figure 2.19: (a) Flow meter (SITRANS F M MAG 1100 F), (b) Pressure transducers
(PMP1400 Druck).
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2.3 Rotary Pumps Simulating MCS
In general, centrifugal pumps are used to produce high pressure gradient and
low flow rate conditions, whereas axial pumps are used to produce low pressure
gradient and high flow rate conditions. The selection of the pump to be used as
an MCS device depends on the pathological condition. The rotational speed in
centrifugal pumps is much lower (2000-6000 rpm) than axial pumps (3000-20000
rpm), whereas the size of centrifugal pumps is, to some degree, larger than the
axial pumps. An axial pump requires less invasive implantation surgery because
it is smaller, whereas centrifugal pumps are more efficient than axial pumps
due to their lower rotational speed and consequently result in less physiological
complications. The typical operating condition for an MCS device implanted in
parallel with the heart is 100 mmHg against 5 lt/min [106], while an MCS device
implanted in the descending aorta, in series with the heart, typically operates at
24± 10 mmHg against 5 lt/min [53, 60, 61, 107].
In this study, two rotary pumps are used to simulate MCS devices. One has a
centrifugal impeller (pump A) and the other has an axial impeller (pump B). Since
this project has been conducted under severe constraints imposed by intellectual
property of the Queen Mary University of London, the hydrodynamic aspects of
the rotary blood pumps A and B are beyond the scope of this thesis and our focus
will be on the hemodynamic responses of the SCVL system with these pumps
integrated and operating at various conditions. The detailed design aspects of
the pumps A and B, including the hydrodynamic and haemocrit performance,
have been published in various internal reports and will be published in relevant
journals in the near future. However, to give the reader an understanding of
the MCS device design process the physical aspects of blood and MCS design
constraints, which are essential to consider for the design of any rotary blood
pumps, are discussed in Sections 2.4 and 2.5, respectively.
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2.4 Physical Aspects of Blood flow
In contrast to an industrial application of rotary pumps in which some hydrody-
namic losses including high shear stress, local recirculation or local acceleration
can be largely neglected, in a clinical application these hydrodynamic losses may
have a remarkable adverse effect on the properties of the blood. As a result,
prior to designing an MCS device, it is important to understand various aspects
of blood properties which may have a direct impact on the design procedure of
an MCS device.
Blood is a combination of different elements including the red blood cells
(RBCs), white cells and platelets suspended in a liquid known as plasma. The
density of blood (1.05 g/cm3) is slightly greater than that of water. Its main
duty in the body is to transfer oxygen as well as nutrients from the left ventricle
to the vital organs and transfer CO2 as well as metabolic waste to the pulmonic
circulation.
RBCs are one of the the most essential elements of the blood. Each individual
RBC has a biconcave disc shape and a diameter and thickness of approximately 8
µm and 2 µm, respectively. The shape of RBCs can deform significantly as they
pass through small arteries and capillaries due to a high shear stress in these
regions.
Problems with high shear stress in rotary blood pumps have stimulated a con-
siderable amount of research on different aspects of blood complications, par-
ticularly RBC fragmentation [108, 109]. For instance, a controlled exam of
shear-induced-haemolysis was conducted by Sutera et al. [108] using a concentric
cylinder viscometer. This showed that high shear stress over a long exposure
time can result in RBC fragmentation leading to the release of a certain level of
haemoglobin into the plasma, which is known as haemolysis. Figure 2.20 shows
the deformation and fragmentation of RBCs after four minutes under various
level of induced shear stress in an experiment conducted by Sutera et al. [108].
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Figure 2.20: Photographs of RBCs at shear stress of (a) 10, (b) 200, (c) 250, (d) 400 Pascals
over the exposure time of 4 min. From: S. P. Sutera et al. [108], Deformation and fragmentation
of human red blood cells in turbulent shear flow, 1975.
Platelets are the other important elements of the blood to be considered for
the design procedure of an MCS device. Platelet activation is the main cause of
thrombus formation in the vicinity of mechanical heart valves or MCS devices.
Platelet activation is more likely to develop in association with stagnant and
recirculating flow or under high shear stress [110]. Once the platelets are activated
they gradually accumulate on the surface and form thrombi at a rate determined
by local flow conditions.
Another important element of the blood which can have a remarkable impact
on an MCS design procedure is the blood viscosity. In a native cardiovascular
system, the blood viscosity in large arteries is independent of the blood shear
rate, thus it behaves as a Newtonian fluid. In small arteries the viscosity varies
with the blood shear rate, thus the blood flow exhibits non-Newtonian behavior.
Also, the viscosity of the blood is highly dependent on the haematocrit level. The
haematocrit level is defined as the fraction of RBC volume to total blood vol-
ume. For instance, for a normal physiological condition where the haematocrit is
about 45%, the blood viscosity is about 0.0036 pa.s [111]. This is about four times
greater than the viscosity of water at room temperature. So any changes occur-
ring on the haematocrit level due to some blood abnormalities such as haemolyis
may have an impact on the blood viscosity.
2 Design and Development of Simulator of the Cardio-Vascular
Blood-Flow Loop 80
2.5 MCS Design Constraints
2.5.1 Pump Size
One of the drawbacks of most first and second generation MCS devices is their
large size. Implantation of a large mechanical device into the patients body
is usually followed by some complications. In particular, very ill patients can
develop severe organ infections, cancer or neurologic damage which may result
in morbidity and mortality [47]. This is mainly due to the highly invasive tissue
dissection surgery which increases the risk of infection [54]. Although the use
of miniatured MCS devices with less invasive surgery may reduce the infection
substantially, it must be noted that in order to meet the required parameters of
the operating condition, the pump needs to be operated at a higher rotor speed
which could potentially increase the risk of blood complications. As a result, it
is highly important to optimise the hydrodynamic performance of the impeller
and casing to minimise the shear stress, exposure time of the blood to contacting
surfaces, local recirculation and stagnation.
2.5.2 Shear Stress and Exposure Time
As indicated in Section 2.4, blood impelled through an MCS device may expe-
rience a significantly higher degree of shear stress compared to a native arterial
system. For smaller MCS devices with a higher rotational speed, the high lev-
els of shear stress between the rotating impeller and casing increases the risk
of blood complications. As a result significant attention should be paid to the
hydrodynamic design of MCS device components. In many studies the maximum
shear stress of 250 Pa has been used as the threshold for haemolysis formation,
however it has been identified that the haemolysis is determined by both shear
stress and exposure time [108]. In general, the RBCs that are exposed for very
short periods can withstand very high level of stress, whereas prolonged exposure
at much lower shear stress may result in some blood complications, particularly
haemolysis and thrombosis. The effect of the shear stress and exposure time on
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the haemolysis has been examined in previous studies [108, 114]. Many investi-
gators have attempted to develop different empirical formulas for evaluation of
the haemolysis level. For instance Giersiepen et al. [115] relates the shear stress
and exposure time to the level of haemolysis, using Equation 2.4.
D = Cατβ (2.4)
where D represents the damage fraction, t represents the time and τ represents
the shear stress. C, α and β are constant values defined in empirical tests.
A wide number of computational fluid dynamic simulations have been con-
ducted to investigate the haemolysis level of a number of MCS devices operating
at various conditions [116, 117, 118, 112]. For instance, Song et al. [117] used
a computational approach to estimate the level of haemolysis of a rotary blood
pump by considering the shear stress histories of a number of particles traveling
across the pump using the Lagrangian tracking method. Taskin et al. [116] per-
formed a study on evaluation of Eulerian and Lagrangian models for haemolysis
estimation. Zhang et al. [112] conducted a computational study on the level of
shear stress in the secondary flow path of a newly developed centrifugal MCS
device.
In order to validate the computational results, it is necessary to conduct in-
vitro haemolysis testing. The experimental haemolysis test involves running the
MCS device in a single loop for a certain period of time with animal blood as the
working fluid. Different studies have been conducted on experimental evaluation
of haemolysis level for a number of MCS devices operating over a certain range
of rotational speeds [119, 112]. For instance, as shown in Figure 2.21 Zhang et
al. [112] conducted an in-vitro test on a newly developed pump, CentriMag, to
validate their computational results on the haemolysis level.
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Figure 2.21: Schematic Diagram of the in-vitro Haemolysis test. From: J. Zhang et al. [112],
Computational and experimental evaluation of the fluid dynamics and hemocompatibility of the
centrimag blood pump, 2006.
2.5.3 Stagnant and Recirculation
Another crucial design constraint for an MCS device is to avoid thrombus forma-
tion. In the worst case scenario, thrombus formation may lead to embolism in
the patients cerebral system which may result in morbidity and mortality. Two
local flow conditions which may increase the risk of thrombus formation are re-
circulating flow and stagnant regions. The incidence of both these conditions is
highly dependent on the hydrodynamic design of the impeller passages. There
are a number of geometrical parameters which can potentially minimise these
local flow conditions. For instance in a centrifugal pump, the selection of num-
ber of blades greatly influences the hydrodynamic and hemolytic performance.
A large number of blade sets reduces recirculation by making the impeller vane
passages become narrower. However, for blood with viscosity four times higher
than water, the larger surface area leads to greater friction and hydraulic losses
which may result in a drop in efficiency and increase the blood temperature. A
wide number of computational and experimental studies have been conducted on
the effect of the impeller geometry on hydrodynamic and hemolytic performance
of a rotary pump [120, 121].
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2.5.4 Secondary Flow Path
Another design constraint which may have a crucial impact on the hydrodynamic
efficiency as well as hemolytic performance of an MCS device is the size of the
clearance gap between the impeller and the casing. For an MCS device there
are two paths for the blood to travel. The primary path is the path through
which the flow travels from the inlet to the outlet of the pump in order to gen-
erate the required flow and pressure. The secondary path exists to separate the
rotating impeller from the stationary casing. The secondary flow path is more
important in centrifugal than in axial pumps because centrifugal pumps generally
have much longer secondary flow paths. Due to the small size and low flow rate
of the secondary flow, there is a risk of haemolysis complications and platelet
activation. Although increasing the size of the secondary flow path may improve
the hemolytic performance, it may compromise the hydraulic efficiency of the
pump. Computational Fluid Dynamic (CFD) simulation has been employed by
a number of researchers [122, 123, 124, 112] to optimise the secondary flow path
sizes leading to a lower risk of blood complications without sacrificing the pump’s
hydraulic efficiency. Figure 2.23 shows a schematic diagram of a centrifugal pump
in which the secondary flow paths are represented by blue arrows.
2.5.5 Active and Passive Bearings
One of the major drawbacks of the second generation MCS devices incorporating
mechanical bearings is the high risk of wear and thrombus formation in vicinity
of the mechanical bearing and sealing due to blood stagnation. The life span of
the second generation MCS device is around five years [125], so they can not be
used for destination therapy. Exclusion of the mechanical bearing can minimise
the shear stress level as well as the chance of stagnant flow formation around the
mechanical bearings, thus eliminating the risk of wear and thrombus formation.
For the third generation MCS devices the mechanical bearings have been replaced
by magnetic bearings [123], hydrodynamic bearings [126], or combinations of
both techniques [127]. Both magnetic and hydrodynamic bearings have their
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own advantages and disadvantages.
The magnetic bearings are categorised into two classifications known as passive
and active. The passive magnetic bearings operate based on the attraction and
repulsion force between two permanent magnets where one is integrated into
the impeller and the other into the casing. The passive magnetic bearing can
create a high clearance gap between the impeller and casing with less complexity
and lower energy consumption. However, from the physical point of view, the
passive magnetic bearings can not be used independently and hence should be
combined with other types of bearings [128]. Similar to the passive magnetic
bearings, the active magnetic bearings can operate at high clearance and thereby
minimise the risk of blood complication. For instance, the UltraMag pump [123],
incorporating an active magnetic bearing, allows the minimum clearance gap
of 500 µm. However, the active magnetic bearing requires a complex feedback
system to control the position of impeller, resulting in high energy consumption.
The passive hydrodynamic bearing system is less complex but requires a min-
imal clearance gap to operate. The passive hydrodynamic bearing systems use
pressure built up between the impeller and casing to generate the thrust in a
similar fashion to journal bearings. For instance, the VentrAssist pump [126],
incorporating passive hydrodynamic bearings requires a clearance gap between
50 and 200 µm for suspension of the impeller. Although the passive magnetic
bearings consume less energy than the active magnetic bearings, it must be noted
that the small clearance gap required for the hydrodynamic bearing may increase
the risk of blood complications over off-design operating conditions.
Figure 2.22 and Figure 2.23 show a schematic diagram of an axial and a cen-
trifugal MCS device, respectively. It must be noted that these two figures are
only to aid understanding and do not represent our MCS devices’ configurations.
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Figure 2.22: Schematic diagram of an axial MCS device implementing two axial active mag-
netic bearings.
Figure 2.23: Schematic diagram of an centrifugal MCS device implementing combination of
active and passive magnets.
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2.6 In-Vitro Test of Pump A and B
A single loop test-rig which will be called O-loop hereafter was developed for
initial testing of pump A and B to find the characteristics of each pump (flow-
rate versus pressure difference at various rotor speeds). The O-loop consists of a
place for the pump installation, a valve to change the resistance of the loop, a flow
meter to measure flow and two pressure transducers for pressure measurement.
Figures 2.24 and 2.27 show the installation of pump A and B in the O-loop test-rig
respectively.
2.6.1 Pump A
Rotary pump A is a centrifugal pump with a maximum pressure difference of
105 mmHg and a maximum flow-rate of 9.5 lt/min at the rotor speed of 2400
rpm. The pump pressure difference was defined by the inlet and outlet pressure
(∆P=P0-Pi). The pressure difference versus flow-rate was recorded while the
circuit resistance was increasing. Figure 2.25 shows the pressure difference versus
flow-rate characteristics of the pump A at nominal impeller speed of 2400 rpm.
The results of pump A implanted in parallel configurations, both connected from
the left ventricle to the descending and the ascending aorta, will be discussed in
Chapter 3.
Figure 2.24: Photograph of centrifugal pump A in the O-loop test bench.
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Figure 2.25: Pressure difference (mmHg) verses flow-rate (lt/min) for pump A.
2.6.2 Pump B
Rotary pump B is an axial pump which has been designed and developed for an
earlier CHF stage III and possibly CHF stage II to slow down and prevent the
progression from stage II to IV with less possible invasive surgery. This pump
produces a maximum pressure difference of 35 mmHg and maximum flow-rate of
10 lt/min at the highest rotor speed.
As shown in Figure 2.26, pump B consists of a high speed BrushLess DC
(BLDC) motor, a controller designed to control the motor speed and a coupling
mechanism to directly drive the rotor of the pump. The rotational speed of the
motor drive has been changed from a low value to a nominal maximum speed
(2400-6000 rpm). The pressure difference versus flow-rate characteristics of the
pump B was investigated under a static flow condition, in the O-loop, as shown
in Figure 2.27.
For monitoring the speed of the motor drive, an oscilloscope device has been
integrated into the system. The applied voltage has been kept constant at 24V
and the drawn current has been measured at each rotational speed to calculate
the electrical input power. At the same time the pressure before and after the
blade have been measured at each rotational speed using two pressure transducers
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Figure 2.26: Photograph of the components of pump B including the high speed motor, the
controller and the coupling.
Figure 2.27: Photograph of the axial pump B in the O-loop test bench.
to calculate the inlet and outlet pressures due to the blade (∆P=P0-Pi). The
corresponding flow due to the blade rotation has been measured at each rotational
speed. All the measurement processes have been repeated for a wide range of
resistances from low to high using a set of Hoffman clip. Figure 2.28 shows the
graph of pressure difference versus flow-rate for the pump B. The results of pump
B implanted in the descending aorta, in series configuration with the heart, will
be discussed in Chapter 3 and Chapter 4. In addition, in Chapter 4, the numerical
model of pump B integrated in the concentrated lumped parameter model will
be examined.
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Figure 2.28: Pressure difference (mmHg) verses flow-rate (lt/min) for the prototyped axial
pump B.
2.7 Implementation of the SCVL System
This chapter evaluates the performance of the SCVL system with simulation of
the physiological and pathological conditions. Three cases have been studied;
controlled condition, congestive heart failure (CHF), left ventricular diastolic
dysfucntion in hypertension condition (LVDDH). In each case the aortic sinus
pressure and the carotid pressure waveforms and Cardiac Output (CO) were
recorded as these are the gold standard of cardiac condition assessment [129].
In all four cases,the experimental aortic sinus pressure waveform and the carotid
pressure waveform are compared to the numerical data obtained with adaptations
of the programs described in previous studies conducted by Korakianitis et al. [98,
99, 100, 101, 102, 103].
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2.7.1 Simulation of Controlled Condition
The pressure waveforms at the aortic sinus and carotid artery for controlled condi-
tion are demonstrated for two cardiac cycles in Figure 2.29(a) and Figure 2.29(b).
In Figure 2.29(a), the dashed line is the clinical aortic pressure waveform ex-
tracted from the study conducted by Fischer et al. [2], the dashed-and-dotted
line is the numerical data, and the solid line is the measured data from the
SCVL. In Figure 2.29(b), the dashed-and-dotted line is the numerical data and
the solid line is the measured signal from the SCVL system. It is evident from Fig-
ure 2.29(a) and Figure 2.29(b) that the aortic sinus pressure waveform is 125/75
mmHg, and the corresponding carotid pressure waveform is 120/72 mmHg. In
both aortic sinus and carotid pressure waveform the dicrotic notch after the aor-
tic valve closure is captured. The Pmc (mean circulatory pressure) of the system
measured in controlled condition and it is 7 mmHg. The CO is measured in the
ascending aorta. In the controlled condition the CO is 5.1 lt/min and the mean
aortic pressure (AoPmean) is 91.7 mmHg.
(a) (b)
Figure 2.29: Comparison of the aortic and carotid pressure waveforms in controlled con-
ditions. (a) aortic pressure is 125/75 mmHg, (b) carotid pressure is 120/72 mmHg, CO is
5.1 lt/min.
2.7.2 Simulation of Congestive Heart Failure Condition
The condition of Congestive Heart Failure (CHF) can be defined as a heart that
becomes severely weakened as a result of cardiovascular disease; mainly my-
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ocardiocardial infarction. As a consequence, the pumping action of the heart
is severely depressed resulting in two main effects: reduced CO and damming up
of blood in the veins leading to an increase in the venous pressure and therefore
increase in the right atrial pressure [10]. To reproduce the CHF condition, the cir-
culating volume of water is increased; Dlvmin is increased in order to increase the
resting left ventricle volume; Dlvmax is decreased with the purpose of mimicking
the reduced left ventricle pumping ability.
(a) (b)
Figure 2.30: Comparison of the aortic and carotid pressure waveforms in CHF condition. (a)
aortic pressure is 115/70 mmHg, (b) carotid pressure is 112/68 mmHg, CO is 2.5 lt/min.
In Figures 2.30(a) and 2.30(b), the dashed-and-dotted line is the numerical
data and the solid line is the measured data from the SCVL. This is evident
in Figure 2.30(a) and 2.30(b), where for both the aortic sinus and the carotid
pressure waveform there is a drop in the end diastolic pressure and the end systolic
pressure, when compared to the controlled condition. The aortic sinus pressure
waveform drops down to 115/70 mmHg and the carotid pressure waveform drops
down to 112/68 mmHg. The AoPmean is 85.5 mmHg. In both the aortic sinus
and carotid pressure waveform the dicrotic notch after the aortic valve closure
is captured. For the CHF condition the CO drops from 5.1 lt/min, in a control
condition, to 2.5 lt/min.
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2.7.3 Simulation of Left Ventricular Diastolic Dysfunction
in Hypertension Condition
In the clinical setting, hypertension is defined as a systolic blood pressure of 140
mmHg or greater and/or a diastolic blood pressure of 90 mmHg or greater [130].
Most hypertensive patients undergo co-existing impaired diastolic relaxation and
therefore impaired left ventricle diastolic filling [131, 132, 133]. Zhou et al. [134]
reported aortic stiffening as the main factor for developing increased left ven-
tricle afterload and consequent Left Ventricle Hypertrophy and Left Ventricle
Dysfunction (LVDDH).
(a) (b)
Figure 2.31: Comparison of aortic and carotid pressure waveforms in LVDDH condition. (a)
aortic pressure is 145/95 mmHg, (b) carotid pressure is 140/90 mmHg, CO is 3.1 lt/min.
To mimic left ventricular disfunction , the aortic compliance, the left ventricular
elastance and the left ventricular resting volume are reduced whereas the total
peripheral resistance is increased. This is achieved by decreasing displacement of
the the left ventricle actuator. In Figures 2.31(a) and 2.31(b), the dashed-and-
dotted line is the numerical data and the solid line is the measured data from the
SCVL system. As it is evident from Figure 2.31(a), there is an increase in both
the end diastolic pressure and the end systolic pressure of the aortic sinus and the
carotid pressure waveform in comparison to the controlled condition. The aortic
sinus pressure waveform has increased to 145/95 mmHg and the carotid pressure
waveform has increased to 140/90 mmHg. The AoPmean is 111.7 mmHg. In both
the aortic sinus and the carotid pressure waveforms the dicrotic notch after the
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aortic valve closure is captured. For the LVDDH condition, cardiac output drops
down from 5.1 lt/min in a controlled condition to 3.1 lt/min.
The results show the capability of the multi-chambers SCVL to reproduce the
aortic sinus and the carotid pressure waveform in control, CHF and LVDDH.
Table 2.2 shows the hemodynamic variables as found with the multi-chamber
SCVL. Using four tubular permanent magnet linear motors working according
to prescribed elastance function of the native ventricles and atria shows the high
success of this technique in emulating the contraction phase and filling phases as
found in the native cardiac muscle.
Table 2.2: Hemodynamic variables for the different modelled cases.
Parameter Control CHF LVDD Unit
AoPsys 125 115 145 mmHg
AoPdia 75 70 95 mmHg
AoPmean 91.7 85.5 117 mmHg
CaPsys 120 112 140 mmHg
CaPdia 72 68 90 mmHg
CaPmean 92 82.7 106.7 mmHg
PaPmean 18 29 28 mmHg
Pmc 7 20 15 mmHg
CO 5.1 2.5 3.1 lt/min
In all replicated physiological cases the dicrotic notch is captured on the aortic
sinus and the carotid pressure waveforms. In comparison to a native pressure
waveform, the dicrotic notch on the experimental results seems slightly bigger.
This can be justified due to the implementation of glass in the aorta artery
segment of the SCVL as the mechanical properties of this material are far from
what is found in native vasculature [4].
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2.8 Summary
This chapter presents a new device designed to simulate in-vitro flow rates, pres-
sures and other parameters representing normal and diseased conditions of the
human cardiovascular system. Such devices are sometimes called bioreactors or
“mock” simulators of the cardio-vascular blood-flow loop (SCVL) in the litera-
ture. Most SCVL systems only simulate the systemic circulation only and have
inherent limitations in studying the interaction of left and right sides of circula-
tion. Those SCVL systems that include both left and right sides of the circulation
utilize header reservoirs simulating cycles with constant atrial pressures.
The SCVL described in this paper includes models for all four chambers of the
heart, and the systemic and pulmonary circulation loops. Each heart chamber is
accurately activated by a separate linear motor to simulate the suction and ejec-
tion stages, thus capturing important features in the pressure waveforms. Four
mechanical heart valves corresponding to the mitral, pulmonary, tricuspid and
aortic are used to control the desired unidirectional flow. This SCVL can emulate
different physiological and pathological conditions of the human cardiovascular
system by controlling the different parameters of blood circulation through the
vascular tree (mainly the resistance, compliance and elastance of the heart cham-
bers). In this study four cases were simulated; control, congestive heart failure
and left ventricular diastolic dysfunction in hypertension conditions. The aortic
sinus and carotid artery pressure waveforms as well as cardiac output have been
investigated. In all cases the experimental results are compared with human
physiology and numerical simulations. The results show the capability of the
SCVL to replicate various physiological and pathological conditions.
Chapter 3
In-vitro Comparison of Two Different MCS Devices
Installed In Series and In Parallel
3.1 Motivation
Congestive Heart Failure (CHF) is the leading cause of death in western coun-
tries. More than seven million people in both North America and Europe are
diagnosed with a condition of heart failure, among whom nearly 6% are cate-
gorised as New York Heart Association (NYHA) class IV heart failure [8]. For
end-stage CHF, two conventional solutions are palliative treatment and cardiac
transplantation. For the former, the patient is hospital-bound under considerable
costly pharmacological treatment and sadly he/she dies after a short period [135].
The latter solution is known as the gold standard for end-stage CHF patients.
Nevertheless, with a limited number of heart donors (≈2500 donor annually)
there remains a considerable rate of mortality (8-10%) in waiting list patients for
cardiac transplant [17]. As a result, the role of Mechanical Circulatory Support
(MCS) devices as a bridge to transplantation and destination therapy has become
vital for patients on and off the waiting list [9, 23, 27].
There are two traditional approaches for MCS device implantation and for
both the pump operates in parallel configuration with the heart. Implantation
of an MCS device between the apex of the left ventricle and the ascending aorta
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(a) (b) (c)
Figure 3.1: (a) Heartware pump in LV-AA configuration. From: M. S. Slaughter et al. [45],
Heartware miniature axial-flow ventricular assist device design and initial feasibility test, 2009.,
(b) Jarvik pump in LV-DA configuration. From: O. H. Frazier [23], Research and development
of an implantable, axial-flow left ventricular assist device: the jarvik 2000 heart, 2001., (c)
Reitan Catheter Pump (RCP) in the descending aorta (DA). From: O. Reitan et al. [53],
Hemodynamic effects of a new percutaneous circulatory support device in a left ventricular
failure model, 2003
(LV-AA), occurs using the median sternotomy and implantation of an MCS de-
vice between the apex of the left ventricle and the descending aorta (LV-DA),
occurs using the left thoracotomy. The former results in a promising hemody-
namic improvement in the blood circulation system. However, due to the deep
dissection process, the operation is prolonged and may cause severe postopera-
tive complications in critically ill patients [48, 55, 56]. The latter is less invasive
and may not necessitate the use of Cardio-Pulmonary Bypass (CPB) during the
operation [24]. However, the LV-DA configuration is not an optimal technique
in a wide range of MCS supports and may lead to a formation of stagnant and
subsequent retrograde flows in the arterial system [54, 58, 59].
Increasing the number of old and sick patients who are no longer eligible for
a prolonged invasive implantation surgery has attracted the attention of most
researchers to investigate the development of an MCS device with more reliabil-
ity and less possible invasive complications that would benefit the majority of
patients.
Recent studies on the Reitan Catheter Pump (RCP), a short-term percuta-
neous circulatory assistant device, implanted in the descending aorta after car-
diogenic shock, suggest that this technique is less invasive than the traditional
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Figure 3.2: Schematic diagram of both in-series and in-parallel configurations.
in-parallel configurations and may have the potential to be employed for the
permanent implantation [53, 60, 61, 107].
Figures 3.1(a-c) compares three different existing configurations. Figure 3.1(a)
shows the Heartware pump in LV-AA configuration [45]. Figure 3.1(b) shows the
Jarvik pump in LV-DA configuration [23]. Figure 3.1(c) shows the RCP in the
descending aorta [53].
Figure 3.2 presents the schematic diagram of MCS device in two series config-
urations (S1 and S2) and MCS device in two parallel configurations (P1 and P2)
with the left ventricle. It is evident that S1 is installed in the ascending aorta
whereas S2 is installed in the descending aorta in series with the heart. The inlet
of both P1 and P2 is connected to the apex of the native left ventricle and the
outlet is connected to the ascending aorta and the descending aorta respectively.
The aim of this chapter is to evaluate the previous findings of the existing
in-parallel deployments [55, 56, 57]. In addition, since currently there is no
comprehensive in-vitro investigation on in-series deployment, the new technique
of inserting an MCS device in the descending aorta has been investigated and
the results have been compared to in-parallel techniques and the advantages and
disadvantages of each have been discussed.
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Figure 3.3: Photograph of the SCVL system with the pump A simulating the LV-AA in-parallel configuration.
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Due to the fact that there are a significant number of numerical studies on the
hemodynamic responses of the cardiovascular system to a rotary pump deployed
in parallel with the heart (LV-AA or LV-DA) [81, 102, 103, 136, 137, 138, 139],
within this chapter we just focus on the in-vitro comparison of the in-parallel and
in-series configurations. Further, inChapter 4 the focus will be on the numerical
and experimental studies on the hemodynamic responses of the cardiovascular
system to a rotary pump deployed in the descending aorta, in-series configuration.
The objectives of the in-vitro test are met by using our in-house multi-chamber
Simulator of the Cardiovascular Blood flow Loop (SCVL) which has been de-
scribed elaborately in Chapter 2 as well as our previous report [140]. The
main purpose of the SCVL sytem is to simulate the pressure waveform features,
closer to a controlled and diseased condition as that found in the clinical setting.
This includes the close replication of all four phases of the cardiac cycle which
is achieved by using individual actuation of four heart chambers through the
implementation of linear motors.
3.2 Methodology
First, the CHF condition was simulated in the SCVL system. Following tasks
were performed to reproduce the diseased condition.
• The circulating volume of water is increased.
• Dlvmin is increased in order to increase the resting left ventricle volume.
• Dlvmax is decreased with the purpose of mimicking the reduced left ventricle
pumping ability.
Figure 3.4 represents a comparison between the slider’s maximum and mini-
mum displacement while simulating a healthy and diseased condition.
The experimental measurements for the desired CHF were validated with the
corresponding clinical data [2, 4, 10, 141]. In each case, the aortic pressure, left
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Figure 3.4: Schematic representation of the linear motor, actuating the left ventricle chamber.
ventricle pressure, carotid pressure waveforms as well as the average systemic
and pulmonic flow-rate were recorded. These variables are the gold standard of
cardiac condition assessment [129].
Due to the narrow size of the carotid artery, the carotid flow couldn’t be
measured directly using the flow-meter, instead the relative change of the carotid
flow (QRca) has been evaluated by measuring the pressure difference across the
carotid artery. According to Poiseuille’s law [142], for a circular pipe, the pressure
difference across the pipe is proportional to the flow past the pipe. As a result, the
QRca has been defined as a function of the carotid pressure difference measured
before and after the pump deployment:
QRca =
Qca,on −Qca,off
Qca,off
× 100 = ∆Pca,on −∆Pca,off
∆Pca,off
× 100 (3.1)
where ∆P(ca) and Q(ca) are the pressure difference and the volumetric flow rate
in the carotid artery respectively. The subscript ’on’ belongs to the condition
where the pump is in operation and ’off’ is when the pump is absent.
In this study, two rotary pumps simulating MCS devices were employed. Pump
A is a centrifugal pump with the rotor diameter of 45 mm producing the maximum
pressure difference of 102 mmHg and maximum flow-rate of 12 L/min and is
used for the in-parallel configurations and pump B is an in-house percutaneous
axial pump with the rotor diameter of 22 mm producing the maximum pressure
difference of 35 mmHg and maximum flow-rate of 10 L/min and is used for the
in-series configuration.
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3.2.1 Configurations
The replication of in-parallel LV-AA and LV-DA techniques were conducted by
connecting the inflow graft to the connulation port, placed at the bottom of the
left ventricle chamber and connecting the outflow graft to the ascending and de-
scending aorta, respectively. Figure 3.5 and Figure 3.6 represent the schematic
diagram of LV-AA and LV-DA techniques, respectively. The outflow graft diam-
eter is 22 mm and the ratio of outflow graft to the aortic artery is nearly 1:1. For
in-parallel techniques (LV-AA and LV-DA), three experiments were conducted in
which the hemodynamic responses of the SCVL system were investigated when
the pump A was operating at three examined Pump Settings (PS), as presented
in Table 3.1.
Table 3.1: Pressure and flow parameters of pump A at examined pump settings.
PS
∆Ppump
(mmHg)
Qpump
(L/min)
0 (off) 0 0
1 98 2.5
2 95 4.5
3 90 5.5
Table 3.2: Pressure and flow parameters of pump B at examined pump settings.
PS
∆Ppump
(mmHg)
Qpump
(L/min)
0 (off) 0 0
1 25 3
2 28 4
The replication of the in-series DA configuration was conducted by placing the
pump B in the proximal descending aorta, below the left subclavian artery and
above the renal arteries, as shown in Figure 3.7. Two experiments were conducted
in which the hemodynamic responses of the SCVL system were investigated when
the pump B was operating at two examined PS, as presented in Table 3.2.
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3.3 Results and Discussion
First, the CHF condition similar to what is found in our previous publication [140]
was reproduced. The experimental measurements for the desired CHF were val-
idated with the corresponding clinical data [2, 4, 10, 141, 143]. In each case, the
aortic pressure, left ventricle pressure, carotid pressure waveforms as well as the
average systemic and pulmonic flow-rate were recorded. These variables are the
gold standard of cardiac condition assessment [129].
3.3.1 In-parallel LV-AA configuration
As shown in Figures 3.8(a-d), the aortic pressure (AoP) and the left ventricular
pressure (LVP) waveforms are demonstrated for two consecutive cardiac cycles.
The dashed lines in all figures represent the clinical data [4]. The solid line is the
measured aortic pressure waveform and the dashed-and-dotted line is the mea-
sured left ventricle pressure waveform from the SCVL system.
Figure 3.5: Schematic diagram of the left ventricle chamber with pump A in-parallel (LV-AA)
configuration.
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Figure 3.6: Schematic diagram of the left ventricle chamber with pump A in-parallel (LV-DA)
configuration.
Figure 3.7: Schematic diagram of pump B installed in the descending aorta, in series config-
uration with the left ventricle.
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Figure 3.8(a) shows the AoP and LVP waveforms for the CHF condition when
the pump is off and the outflow graft is fully clamped. The AoP and LVP
waveforms are 104/81 and 104/30 mmHg, respectively. It can be observed that
the experimental AoP is in good agreement to the corresponding clinical data [4].
The use of four tubular permanent magnet linear motors, working according to
the prescribed elastance function of the native ventricles and atria shows the high
success of this technique in emulating pressure waveform features in very close
agreement to the clinical setting. The small bump reflected on the descending
limb of the aortic pressure waveform is the dicrotic notch (Incisura) and the small
pressure bump reflected just before the ascending limb of the LVP waveform
represents the systolic atruim contraction.
Figure 3.8(b-d) show the AoP and LVP waveforms at PS 1, 2 and 3, respec-
tively. It is evident that, at PS 1, the AoP and LVP waveforms are 102/89
and 102/25 mmHg, at PS 2, the AoP and LVP waveforms are 97/95 and 92/15
mmHg and at PS 3, the AoP and LVP waveforms are 107/105 and 85/8 mmHg,
respectively.
At PS 0 and 1, the aortic end-systolic pressure (AoPsys) is equal to the left
ventricle end-systolic pressure (LVPsys) implying that at these levels, the aortic
valve is still active and thus the left ventricle pumping action contributes part
of the cardiac circulation. However, at PS 2 and 3, AoPsys is no longer equal to
LVPsys implying that the continuous flow from the pump is taking over the left
ventricle pulsatile flow, leading to the closure of the aortic valve. Referring to
Figure 3.8(a-d), it can be observed that by increasing the pump setting from 1 to
3, the end-diastolic left ventricle pressure LVPdia drops by 83%. A drop in LVPdia
leads to a lower volume expansion and thus lower ventricular wall stress during
the filling phase. This may assist with the recovery of the damaged myocardial
cells in a native system, as indicated by Frazier et al. [144].
Figures 3.9(a-d) show the carotid pressure (CaP) waveforms for two consecutive
cardiac cycles. The dashed line in all figures represent the the clinical data for
the CHF condition [141]. The solid line is the measured CaP waveform from the
SCVL system. As shown in Figure 3.9(a) at PS 0, the CaP waveform is 110/77
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Figure 3.8: (a) AoP and LVP for the CHF condition, Qao,mean=2.5 L/min (b) AoP and LVP
at PS 1, Qao,mean=3.5 L/min (c) AoP and LVP at PS 2, Qao,mean=4.3 L/min (d) AoP and
LVP at PS 3, Qao,mean=5.4 L/min. The clinical AoP waveforms under CHF condition [4] are
shown in all plots for clearer comparison.
Figure 3.9: (a) CaP for the CHF condition, (b) CaP at PS 1, (c) CaP at PS 2, (d) CaP at
PS 3. The clinical CaP waveforms under CHF condition [141] are shown in all plots for clearer
comparison.
mmHg which is in good agreement with the clinical data. As the pump setting
is increased from 1 to 3, the end diastolic carotid pressure (CaPdia) increases
considerably while the end systolic carotid pressure (CaPsys) decreases slightly.
The Pulse Pressure (PP) is determined by subtracting the end-diastolic pres-
sure from the end-systolic pressure [10]. Figure 3.10 compares the aortic and
carotid PP with and without the pump. The dashed lines are the aortic and
carotid PP in a healthy condition (control) [2, 143] and the solid lines are the
measured aortic and carotid PP for the CHF condition at different pump set-
tings. Considering the aortic and carotid PP of 40 and 46 mmHg, respectively
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Figure 3.10: The aortic and carotid PP for the CHF condition without the pump and with
the pump A at PS 1, 2 and 3. The aortic PP [2] and carotid PP [143] under a healthy condition
(control) are plotted as the reference lines.
for the healthy condition, the aortic and carotid PP under the CHF condition
drops by 41 and 30%, respectively. When the pump setting is changed from 1 to
3, the aortic PP drops further from 13.1 to 1 mmHg. The carotid PP follows the
trend and drops from 21.58 to 7.52 mmHg. It is concluded that increasing the
level of continuous flow into the ascending aorta leads to a substantial reduction
in pulsatility which may cause some disturbances for end-organ functionality as
indicated by Kim et al. [40].
The mean aortic flow (Qao,mean) was measured, downstream of the outflow graft,
in the ascending aorta, as shown in Figure 3.5. The Qao,mean for the replicated
CHF condition was recorded as 2.5 L/min. When the pump setting was increased
from 1 to 3, it was observed that the Qao,mean improved from 3.4 to 5.4 L/min at
100% contribution of the pump A. As the pump setting was increased from 1 to
3, the relative change of the carotid flow (QRca) increased from 3.5 to 8.5%. The
positive QRca indicates that for the LV-AA configuration, regardless of the level
of pump support, there will be no carotid perfusion drop. The average Pulmonic
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artery Pressure (PaPmean) and the average pulmonic flow (Qpa,mean) were recorded
at each pump setting. For the CHF condition, PaPmean and Qpa,mean were recorded
as 30 mmHg and 2 L/min, respectively. When the pump setting was increased
from 1 to 3, PaPmean dropped to 8 mmHg and Qpa,mean improved to 4.6 L/min.
Table 3.4 represents the hemodynamic results for in-parallel LV-AA configuration.
It is found that the implementation of the in-parallel LV-AA configuration
leads to significant improvement in the systemic and the pulmonic perfusion
when the pump contribution is increased. No stagnant region was observed in the
aortic arch region over the whole cardiac cycle for the examined pump settings.
However one of the adverse effects which was observed after employing the LV-
AA configuration was the presence of irregular flow patterns in vicinity of the
aortic valve. At PS 1, the interaction between the cardiac pulsatile flow and the
pump continuous flow at their junction produced a lot of irregular flow patterns
in this region. Hence it was concluded that the flow regime is of the turbulent
type. At PS 2 and 3, although the pulsatile flow was absent in the case, the
calculated Reynolds number in the outflow graft was higher than the critical
Reynolds number (i.e. Re'4000 for the pipe flows [142]) which was an indication
of the flow being turbulent. Table 3.3, illustrates the calculated Reynolds number
in the outflow graft for the examined pump settings.
Although the turbulent regime may have some adverse affect on the aortic
valve opening-closing mechanism, it can prevent the complete stagnant flow near
the coronary arteries that otherwise would have occurred in the sinus artery upon
the valve closure at higher pump settings. In addition, at higher pump settings,
the turbulent flow may cause some disturbances in blood properties in a native
cardiovascular system [55].
Table 3.3: Reynolds number in the outflow graft for the examined pump settings.
PS
Reynolds
number
1 2408
2 4340
3 5308
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Table 3.4: Hemodynamic results for the in-parallel LV-AA configuration.
Parameters Baseline PS 1 PS 2 PS 3 Unit
LVPsys 104 102 92 85 mmHg
LVPdia 30 25 15 5 mmHg
AoPsys 104 102 97 107 mmHg
AoPdia 81 89 95 105 mmHg
AoPmean 88.7 93.3 95.7 105.7 mmHg
PPao 23.25 13.1 2 1 mmHg
CaPsys 107.5 104 101.5 104.5 mmHg
CaPdia 75.5 82.5 89 97 mmHg
CaPmean 86.2 89.7 93.2 99.5 mmHg
PPca 31.5 21.5 12.5 7.5 mmHg
PaPmean 30 26 22 19 mmHg
Qpo,mean 2 3 3.6 4.6 L/min
Qao,mean 2.5 3.4 4.3 5.4 L/min
QRca - 3.5 6 8.5 %
3.3.2 In-parallel LV-DA configuration
Figure 3.11: (a) AoP and LVP for the CHF condition, (b) AoP and LVP at PS 1, (c) AoP and
LVP at PS 2, (d) AoP and LVP at PS 3. The clinical AoP waveforms under CHF condition [4]
are shown in all plots for clearer comparison.
Figure 3.11(a) shows the AoP and LVP waveforms for the CHF condition with
the same characteristics found in Section 3.3.1. Figure 3.11(b) shows that at
PS 1, the AoP and LVP waveforms are 102/80 and 102/10 mmHg, respectively.
Figure 3.11(c) shows that at PS 2, the AoP and LVP waveforms are 102/92 and
92/7 mmHg, respectively. Figure 3.11(d) shows that at PS 3, the AoP and LVP
are 108/105 and 80/4 mmHg, respectively.
It is evident that at PS 0 and 1, AoPsys is equal to LVPsys implying that at
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Figure 3.12: (a) CaP at the CHF condition, (b) CaP at PS 1, (c) CaP at PS 2, (d) CaP at
PS 3. The clinical CaP waveforms under CHF condition [141] are shown in all plots for clearer
comparison.
these levels the aortic valve is still active and thus the left ventricle pumping
action contributes a part of the cardiac circulation. However, at PS 2 and 3,
AoPsys is no longer equal to LVPsys implying that the continuous flow from the
pump is taking over the left ventricle pulsatile flow leading to the closure of the
aortic valve. It is observed that as the pump setting is increased from 1 to 3, the
LVPdia drops by 85% leading to a lower ventricular wall stress during the filling
phase.
Figures 3.12(a-d) show the CaP waveforms for two consecutive cardiac cycles.
As the pump setting is increased from 1 to 3, similar to LV-DA configuration,
the carotid PP drops substantially.
Figure 3.13 compares the aortic and carotid PP for the CHF condition without
the pump and with the pump in LV-DA configuration. When the pump setting
is changed from 1 to 3, the aortic PP drops from 18.5 to 6.2 mmHg. The carotid
PP follows the trend and drops from 32 to 23 mmHg. Comparing Figure 3.10
and Figure 3.13, it is found that as the pump support level is increased into the
SCVL system, both the aortic and carotid PP gradient falls with slower rate in
LV-DA than LV-AA configuration. This can be as a result of the adverse pressure
occurring due to the continuous retrograde flow from the pump and thus prevent
the AoPsys and CaPsys from dropping considerably [23].
As shown in Figure 3.6, for the LV-DA configuration in the systemic loop,
two flow measurement tests were conducted. One at the downstream of the
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Figure 3.13: The aortic and carotid PP for the CHF condition without the pump and with
the pump A at PS 1, 2 and 3. The aortic PP [2] and carotid PP [143] under a healthy condition
(control) are plotted as the reference lines.
aortic valve to record the ascending aortic flow-rate (Qao,asc) and the other one
in the descending aorta, downstream of the pump outflow graft, to record the
abdominal perfusion (Qao,des). The results showed that as the pump setting
was increased, Qao,asc dropped whereas the Qao,des increased. At PS 3, Qao,asc
dropped to 0 L/min whereas Qao,asc increased to 4.9 L/min. Having stationary
flow in the ascending aorta (Qao,asc=0 L/min) indicate that the retrograde flow
from the pump is taking over the aortic arch and prevents the cardiac flow to
move forward. As the pump setting was increased from 1 to 3, the QRca increased
from 4.5 to 10.5% implying that, similar to the LV-AA configuration, there is no
carotid perfusion drop. Table 3.5 represents the hemodynamic results for the
in-parallel LV-DA configuration at various pump settings.
Using the in-parallel LV-DA configuration has shown a significant flow im-
provement in the descending aorta and other abdominal extremities as the pump
setting was increased. It was observed that for PS 0 and 1, the left ventricle
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Table 3.5: Hemodynamic results for the in-parallel LV-DA configuration.
Parameters Baseline PS 1 PS 2 PS 3 Unit
LVPsys 104 102 92 80 mmHg
LVPdia 30 10 7 4 mmHg
AoPsys 104 101 100 109 mmHg
AoPdia 81 82 90 103 mmHg
AoPmean 88.7 88.3 93.3 105 mmHg
PPao 23 19 10 6 mmHg
CaPsys 107.5 112 113 112 mmHg
CaPdia 75.5 80 84 89 mmHg
CaPmean 86.2 90.7 93.7 96.7 mmHg
PPca 32 32 29 23 mmHg
PaPmean 30 28 24 20 mmHg
Qpo,mean 1.5 2.4 3.5 4.1 L/min
Qao,des 2.4 3.3 4.1 4.9 L/min
Qao,asc 2.5 1.8 0.7 0 L/min
QRca - 4.5 7 10.5 %
chamber is contributing considerable pulsatile normograde flow into the aortic
arch region, the carotid artery and other upstream branches. At PS 2, there is
a combination of normograde flow produced by the left ventricle and retrograde
flow produced by the pump into the descending aorta. From PS 1 to 2, the
retrograde flow gradually overtake the normograde flow in the aortic arch. Con-
sequently, at PS 3, the aortic arch has a region with the stagnant flow in which
the aortic valve remains closed. This may lead to a thrombogenesis condition in
the vicinity of the aortic valve in a native cardiovascular system and ultimately
may lead to some aortic valvular abnormality [40].
3.3.3 In-Series DA configuration
Figure 3.14(a) shows the measured AoP and LVP for the CHF condition. The
AoP and LVP waveforms are 101/79 and 101/25 mmHg, respectively. Fig-
ure 3.14(b-c) show the AoP and LVP waveforms at PS 1 and 2 of pump B,
respectively. It is evident that at PS 1, the AoP and LVP waveforms drop to
94/66 and 94/17 mmHg and at PS 2, the AoP and LVP waveforms drop further
to 84/53 and 84/10 mmHg, respectively.
It is evident that at PS 1 and 2 of pump B, the AoPsys is equal to the LVPsys
waveform, indicating that for in-series DA configuration, regardless of the level
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of pump support the aortic valve is active, hence the left ventricle delivers the
Cardiac Output (CO) into the systemic circulation. The presence of the pulsatile
CO reduces the risk of clotting and thrombus formation in vicinity of the aortic
valve in a native system [41].
Figure 3.14: (a) Experimental and clinical AoP and LVP waveforms for the CHF condition
(b) Experimental AoP and LVP waveforms with the pump B at PS 1, (c) Experimental AoP and
LVP waveforms with the pump B at PS 2. The clinical AoP waveforms under CHF condition [4]
are shown in all plots for clearer comparison.
Figure 3.15(a) shows the experimental and clinical CaP for the CHF condition.
It is evident that the experiment CaP waveforms is 110/76 mmHg. Figure 3.15(b)
and Figure 3.15(c) show the CaP waveforms at PS 1 and 2 of pump B in which
the CaP drops to 108/58 and 105/45 mmHg, respectively.
Figure 3.16 compares the aortic and carotid PP with and without the pump.
It is observed that when the pump B is introduced into the system at PS 1, the
aortic and carotid PP improve by 10 and 57%, respectively. At PS 2 the aortic
and the carotid PP increase by 26 and 69%, respectively. It is concluded that
an increase in the pump support level results in an improved pulsatility of the
pressure waveforms. This is in contrast to the in-parallel configurations where
an increase in the level of pump support alleviates the pulsatility. It has been
3 In-vitro Comparison of Two Different MCS Devices Installed In
Series and In Parallel 113
Figure 3.15: (a) Experimental and clinical CaP waveforms for the CHF condition (b) Ex-
perimental CaP waveforms with the pump B at PS 1, (c) Experimental CaP waveforms with
the pump B at PS 2. The clinical CaP waveforms under CHF condition [141] are shown in all
plots for clearer comparison.
reported that pulsatility has a crucial effect on recovery of the cerebral, renal
and myocardial blood perfusion [40, 41, 42]. As a result, using the in-series
configuration may have better influence on end-organ functionality due to an
improved PP in comparison with the in-parallel configurations.
Figure 3.17(a) and Figure 3.17(b) show the pressure difference waveforms across
the pump B, in the descending aorta, while the SCVL system is in operation. The
solid line represents the measured pressure waveform in the descending aorta for
the CHF condition when the pump is not active. The dashed line and dashed-
dotted line represent the pressure waveforms at the downstream and the upstream
of the pump, respectively. At PS 1, the average pressure difference across the
pump and the average flow-rate past the pump were recorded as 25 mmHg and
3 L/min, respectively. When the pump support level was switched to PS 2 the
average pressure difference was 28 mmHg and the average flow-rate past the pump
was improved to 3.6 L/min.
It is evident in Figure 3.17(a) and Figure 3.17(b), where the difference be-
tween the pressure drop is lower than the difference between the pressure rise.
Peripheral resistance and the pump rotor speed are two main factors affecting
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Figure 3.16: Aortic and carotid PP for the CHF condition without and with the pump B at
PS 1 and 2. The aortic PP [2] and carotid PP [143] under a healthy condition (control) are
plotted as the reference lines.
the pressure difference across the pump. Peripheral resistance is auto-regulated
in a native body whereas the rotor speed is a controllable variable. So, depending
on the stage of the disease, both pressure drop and pressure rise are beneficial.
Pressure drop, at the upstream of the pump, reduces the after-load pressure in
the arterial system and hence minimises the ventricular wall stress. This leads to
more convenient unloading of the chamber and may also assist with the recovery
of the damaged myocardial cells [144]. Also, the pressure rise, at the downstream
of the pump may improve the renal function in patients suffering from the renal
impairment, as demonstrated by Zanardo et al. [145].
The CO for the replicated CHF condition was recorded as 2.8 L/min. When
the pump setting was switched from 1 to 2, it was observed that the CO improved
from 3.4 to 4 L/min. Table 3.6 represents the experimental results of the SCVL
with the pump B operating in the descending aorta.
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Figure 3.17: (a) Experimental descending aortic pressure without the pump and with the
pump B at PS 1 (b) Experimental descending aortic pressure without the pump and with the
pump B at PS 2.
One of the crucial concerns of implantation in the descending aorta is the
blood perfusion disturbances in the brain that may occur due to the pressure
drop generated by the pump. A comparison between the measured QRca with
and without the pump shows a drop of 12.5 to 16.6% at PS 1 and 2, respec-
tively. However, it must be noted that in a native human cardiovascular system,
cerebral blood flow is well autoregulated within 60-140 mmHg of AoPmean and
the local blood flow feedback control provides enough blood perfusion within this
limit [53, 107, 60, 61]. In addition, there is a concern that pressure drop in the
aortic sinus may reduce the coronary flow perfusion. It must be noted that the
coronary perfusion is controlled via a complex autoregulation mechanism and is
dependent on the myocardial oxygen demand [10]. This study has shown that
with the pump in series, the left ventricular internal pressure decreases dramat-
ically implying that the myocardial oxygen demand to overcome the after load
pressure may drop subsequently. It is evident that a declined heart oxygen de-
mand will have a significant effect on the coronary autoregulation mechanism
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Table 3.6: Experimental results from the SCVL with the pump B in the descending aorta
Parameters Baseline PS 1 PS 2 Unit
LVPsys 104 94 84 mmHg
LVPdia 25 17 10 mmHg
AoPsys 104 94 84 mmHg
AoPdia 79 66 53 mmHg
AoPmean 87.3 75.3 63.3 mmHg
PPao 25 28 31 mmHg
CaPsys 110 108 105 mmHg
CaPdia 76 58 48 mmHg
CaPmean 87.3 74.7 67 mmHg
PPca 34 52 59 mmHg
PaPmean 25 22 19 mmHg
Qpo,mean 2 2.2 2.9 L/min
∆Ppump - 25 28 mmHg
COmean 2.8 3.4 4 L/min
QRca - -12.5 -16.6 %
which may compensate the coronary perfusion in a native system. These are the
questions needs to be addressed through an in vivo test.
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3.4 Summary
The objective of this study is to investigate the novel approach of placement of
the pump in the descending aorta and compare it with the traditional approaches
of the Left Ventricle to Ascending Aorta (LV-AA) and the Left Ventricle to De-
scending Aorta (LV-DA). Tests were conducted by using the in-house Simulator
of the Cardio-Vascular blood-flow Loop (SCVL). The results indicate that the
use of in-parallel LV-AA configuration leads to a significant improvement in the
systemic and the pulmonic flow as the level of continuous flow is increased. The
use of LV-DA in-parallel technique leads to an improvement in the systemic and
pulmonic flow at lower level of continuous flow but at higher level of support leads
to a flow retrogradation. In both in-parallel approaches (LV-AA and LV-DA),
increasing the level of MCS continuous flow leads to a decrease in the aortic and
the carotid pulse pressures to a certain extent. The results of the in-series config-
uration show that the pressure drop upstream of the pump facilitates the cardiac
output as a result of the after-load reduction. Also the pressure rise downstream
of the pump may assist the renal perfusion. At the same time the generated
pressure drop at the proximal part of the descending aorta induces a slight drop
in the carotid perfusion which will be autoregulated by the brain in a native
cardiovascular system. The pulse wave analysis shows that the placement of the
pump in the descending aorta, in series with the heart, leads to improved pul-
satility which is beneficial for end-organ functionality in the native cardiovascular
system.
Chapter 4
Numerical and in-vitro Investigation of a Novel MCS
Device Installed in the Descending Aorta
4.1 Motivation
Congestive Heart Failure (CHF) as a result of different heart diseases is one of the
leading cause of death in men and women alike. Patients with severe heart failure
suffer from renal impairment and pulmonary hypertension [11]. Cardiac trans-
plantation is the most established solution for end-stage CHF patients. However,
among 4,200,000 patients suffering from end-stage heart failure in North Amer-
ica and Europe, only a minority of young patients (≤50 year old) are eligible for
cardiac transplantation and the rest are not able to meet the risk criteria. Donor
heart supply meets less than 2% of the demand for eligible patients and leaves the
great majority of patients under palliative treatment [17]. As a result, the role
of Mechanical Circulatory Support (MCS) devices as a bridge to transplantation
for patients on the waiting list and as a bridge to destination for patients off the
waiting list has become vital [9, 23, 27].
The implantation of an MCS device between the left ventricle and the ascending
aorta or between the left ventricle and the descending aorta is prolonged and
highly invasive [24, 48, 55, 58, 59]. A significant number of patients with a
critical physiological or pathological condition are not eligible for a long invasive
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implantation surgery. It is also reported that those patients experiencing long
invasive surgery may suffer from postoperative complications such as infection,
end-organ injury or internal bleeding [9, 54, 56]. As a result, looking for a less
invasive implantation technique which can be utilized in a variety of patients has
become a recent area of interest.
Recent studies on the Reitan Catheter Pump (RCP), a temporary paracorpo-
real MCS device, inserted percutaneously into the descending aorta to prevent
cardiogenic shock, suggests that the descending aorta can be a promising lo-
cation to install a long-term implantable MCS device with minimally invasive
surgery [53, 60, 61]. However, there is a theoretical concern that as the pump is
operating in the descending aorta, there may be a ”steal” phenomenon of blood
flow from the brain and upper extremities.
In addition, there is a question associated with the effect of the pressure rise on
renal perfusion. Renal impairment has been known as a high risk factor of mor-
tality in end-stage CHF patients. The heart and kidneys are two interdependent
organs. So, any heart dysregulation may cause the renal function to deteriorate
and in contrast any pharmacological therapy to alleviate the condition of CHF
may have further adverse effects on renal function [146].
The aim of this study is to conduct numerical and experimental investigations
on the hemodynamic responses of the cardiovascular system aided with an MCS
device operating in the descending aorta.
The numerical simulations of the cardiovascular system allow for the investi-
gation into the hemodynamic parameters of the whole circulatory system which
is not feasible in a native human body due to the complexity of the system. In
general, the numerical models are classified as distributed parameter models and
concentrated parameter models. The distributed parameter models are employed
to investigate the local dynamics in certain parts of the cardiovascular system,
such as for simulation of the heart [147]. The general distributed parameter
model includes computational fluid dynamics, finite elements and the transmis-
sion line method [98]. In contrast, the concentrated parameter models are used
for investigation of the global response of the cardiovascular system [136].
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In this study, the objectives of the numerical study are met using the modified
version of the Concentrated Lumped Parameter (CLP) model, adapted from the
programs described in different studies conducted by Korakianitis et al. [98, 99,
100, 101, 102, 103]. As an improvement from previous studies, the original CLP
model has been updated from C language into the Simulink environment of the
MATLAB program. In addition, to study the hemodynamic responses of the
upper and lower extremities to the pump operating in the descending aorta, the
carotid circulation and the renal circulation compartments have been added to
the systemic loop.
Figure 4.1: Schematic diagram of the CLP model with the pump integrated in the descending
aorta.
The design and implementation of mechanical cardiovascular simulators has
been motivated by the necessity and significance of in-vitro tests of various arti-
ficial devices such as heart valves, ventricular assist devices (VAD), MCS devices
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etc. prior to in-vivo tests.
In general, cardiovascular simulators are classified into three main categories
based on the number of actuators replicating the heart chambers. Single-chamber
SCVL systems are used for the investigation of newly developed time-varying elas-
tance functions of the left ventricle [148]. Twin-chamber SCVL systems are used
for the investigation of the hemodynamic responses of the heart to implanted
various prosthetic devices [84] and multi-chamber SCVL are used for the investi-
gation of the central and peripheral hemodynamic variables of the systemic and
the pulmonary circulations simultaneously [83]. In this study, the objectives of
the experimental study are met using our in-house multi-chamber Simulator of
Cardio-Vascular Loops (SCVL) described in Chapter 2. The main purpose of our
multi-chamber SCVL is to simulate the pressure waveform features, closer to a
controlled and diseased condition as that found in the clinical setting. This in-
cludes the close replication of all four phases of the cardiac cycle which is achieved
by using individual actuation of four heart chambers through the implementation
of linear motors.
4.2 Numerical Study
Figure 4.1 shows the schematic diagram of the CLP model with the MCS device
integrated in the descending aorta. The CLP model is classified into two sections:
the heart and the blood circulation loop. The heart chambers are modelled
with the time-varying elastance concept originally described by Suga et al. [93].
The local effects of the systemic and the pulmonic loops are modelled with the
resistance, capacitance and inductance (RCL) components based on the modified
version of the Windkessel model [149]. Figure 4.2 shows the Simulink environment
of the cardiovascular system with the pump integrated in the descending aorta.
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Figure 4.2: Simulink environment of the CLP model with the numerical model of pump B
integrated in series with the heart.
4 Numerical and in-vitro Investigation of a Novel MCS Device
Installed in the Descending Aorta 123
4.2.1 Heart Model
The heart is modelled by four chambers. Each chamber is activated separately
according to the corresponding time-varying elastance model, originally described
by Suga et al. [93]. The volume of each chamber is evaluated through the flow-rate
difference between the outlet and the inlet of the chamber. The pressure variation
inside the chamber is a linear function of the volume and the corresponding
elastance model. Considering the left ventricle for instance, the instantaneous
left ventricle volume variation is described as the flow-rate difference between the
mitral and aortic valves:
dVlv
dt
= Qmi −Qao (4.1)
The time-varying elastance model of the left ventricular chamber is a function
of the left ventricular characteristics and the activation function.
Elv(t) = Elvmin +
Elvmax − Elvmin
2
elv(t) (4.2)
where Elv(t) represents the time-varying elastance as a function of the max-
imum and the minimum elastance of the chamber (Emax and Emin) and elv(t)
represents the activation function as adopted from different studies conducted by
Korakianitis et al. [98, 99, 100, 101, 102, 103].
elv(t) =


1− cos
(
t
Tvc
pi
)
: 0 ≤ t < Tvc
1 + cos
(
t− Tvc
Tvf − Tvc
pi
)
: Tvc ≤ t < Tvf
0 : Tvf ≤ t < T
(4.3)
where Tvc and Tvf are related to the time to reach the maximum contraction
and that to initiate chamber filling of the ventricle, respectively. Subsequently,
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the pressure in the left ventricle is evaluated through the linear relation between
instantaneous volume and time-varying elastance value.
Plv(t) = Elv(Vlv(t)− Vlv,0) (4.4)
where Plv(t) and Vlv(t) are the left ventricular pressure and volume respectively
and Vlv,0 is the fixed volume-axis intercept, described by Suga et al. [93]. The
model for the right ventricle is similar to that for the left ventricle, apart from
the values of parameters.
The atrium model is in close agreement with the ventricle model with differ-
ent values. Also the form of activation function is derived based on the atrium
dynamic action. Considering the left atrium for instance, the time-varying elas-
tance model of the atrium chamber is a function of the atrium characteristic and
activation function.
Ela(t) = Elamin +
Elamax − Elamin
2
ela(t) (4.5)
where Ela(t) represents the time-varying elastance as a function of the maxi-
mum and the minimum elastance of the chamber (Emax and Emin) and ela(t) rep-
resents the activation function as adopted from studies conducted by Korakianitis
et al. [98, 99, 100, 101, 102, 103].
ela(t) =


0 : 0 ≤ t < Tac
1− cos
(
t− Tac
Taf − Tac
2pi
)
: Tac ≤ t < Taf
0 : Taf ≤ t < T
(4.6)
where Tac and Taf are related to the time to reach the maximum contraction
and that to initiate chamber filling of the atrium, respectively. The model for the
right atrium is similar to that for the left atrium with different parameter values.
Figure 4.3 represents the elastance change in both the ventricles as well as the
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atriums simulating the desired CHF condition during a typical heart cycle.
Figure 4.3: Elastance change in the left and right ventricles and the left and right atriums
during a typical heart cycle modelling the desired CHF condition.
Figure 4.4 represents the heart block diagram in the Simulink environment.
The heart block diagram is divided into two block diagrams for each side. Fig-
ure 4.5 represents the left side of the heart which is further subdivided into four
block diagrams including the left atrium, the mitral valve, the left ventricle and
the aortic valve. The left ventricle block diagram is modelled according to Equa-
tions (4.1), (4.2), (4.3) and (4.4) and the left atrium block diagram is modelled
according to Equations (4.1), (4.4), (4.5) and (4.6). Figure 4.6 represents the
right side of the heart which is further divided into four block diagrams includ-
ing the right atrium, the tricuspid valve, the right ventricle and the pulmonic
valve. The model for the right ventricle and the right atrium are similar to that
for the left ventricle and the left atrium, respectively apart from the values of
parameters.
The opening-closing mechanism of each valve is a function of the angular posi-
tion of the valve leaflets. Considering the aortic valve for instance, the pressure-
flow relation in the aortic valve can be evaluated by the orifice model adopted
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Figure 4.4: Block diagram of the heart.
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Figure 4.5: Right side of the heart block diagrams including the right atrium, the tricuspid
valve, the right ventricle and the pulmonic valve.
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Figure 4.6: Left side of the heart block diagrams including the left atrium, the mitral valve,
the left ventricle and the aortic valve.
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from Granet et al. [142].
Qao =
{
CQao.ARao.
√
Plv − Psas : Plv ≥ Psas
CQao.ARao.
√
Psas − Plv : Plv < Psas
(4.7)
where CQao is the aortic flow coefficient and ARao is the area ratio of the aortic
valve. According to Equation (4.8), the ARao is a function of the aortic leaflet
opening angle (θ) as well as the aortic valve radius (rao):
ARao =
pi[rao(1− cosθ)]2
pi[rao(1− cosθmax)]2
=
(1− cosθ)2
(1− cosθmax)2
(4.8)
The θ is evaluated by considering various factors that affect the leaflet motion.
These include the moment due to the pressure difference across the valve, the
moment generated by the shear stress on the leaflet due to fluid flow, the moment
produced by the frictional force and the moment generated by the vortex near
the valve leaflet surface. Here, the θ is computed using Equation (4.9) described
by Korakianitis et al. [98, 99, 100, 101, 102, 103]:
Iao
d2θ
dt2
= kp,ao(Plv − Psas)Aaocosθ − kf,ao
dθ
dt
(4.9)
where Iao is the inertial moment of rotating and Aao is the sectional area of the
aortic valve. kp,ao and kf,ao are the coefficients corresponding to the effect of the
pressure force and frictional action, respectively. The models for the other three
valves are similar to that for the aortic valve with different values.
In this study, most of the hemodynamic variables for a desired CHF condition
are assigned values based on the studies conducted by Korakianitis et al. [98, 99,
100, 101, 102, 103] and the rest are based on the clinical data [2, 4, 10, 141].
The time parameters are listed in Table 4.1. The input parameters for the right
and the left side of the heart to simulate the prescribed CHF are presented in
Tables 4.2. The input coefficients for the valves are presented in Table 4.3.
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Table 4.1: List of time parameters.
Parameter Value Unit
HR 70 bpm
T 1.0 s
Tvc 0.3 s
Tvf 0.45 s
Tac 0.85 s
Taf 1.0 s
Table 4.2: Parameter of the heart for the CHF condition.
Part Parameter Value
Left heart CQao(ml/(s mm Hg0.5)) 350
CQmi(ml/(s mm Hg
0.5)) 400
Elv,max(mmHg/ml) 2.5
Elv,min(mmHg/ml) 0.4
Vlv,0(ml) 5
Ela,max(mmHg/ml) 1
Ela,min(mmHg/ml) 0.2
Vla,0(ml) 4
Right heart CQpo(ml/(s mm Hg0.5)) 350
CQti(ml/(s mm Hg
0.5)) 400
Erv,max(mmHg/ml) 1.5
Erv,min(mmHg/ml) 0.35
Vrv,0(ml) 1
Era,max(mmHg/ml) 0.7
Era,min(mmHg/ml) 0.2
Vra,0(ml) 1
4.2.2 Blood Circulation Loop
The blood circulation loop has been divided into the systemic and the pulmonary
loops. Each loop consists of a number of components representing the artery, ar-
teriole, capillary and vein. Each component is modelled by a series of resistance,
compliance and inductance (RCL) similar to the fashion described by Lim et
al. [137, 150]. Each RCL component has been tuned based on the local effects
Table 4.3: Coefficients for variable valve opening modeling.
Part Parameter Value
Left side Kp,ao(m/(s2mmHg)) 5500
Kf,ao(s
−1) 50
Kp,mi(m/(s
2mmHg)) 5500
Kf,mi(s
−1) 50
Right side Kp,po(m/(s2mmHg)) 5500
Kf,ppo(s
−1) 50
Kp,ti(m/(s
2mmHg)) 5500
Kf,ti(s
−1) 50
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Figure 4.7: Aortic sinus, aortic arch and lower limbs block diagrams.
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Figure 4.8: Pulmonary artery sinus, pulmonary artery and pulmonary vein block diagrams.
of friction, elasticity and inertia of the blood. Considering the pulmonary artery
compartment from Figure 4.1 as an example, the dynamic pressure and the dy-
namic flow have been obtained from the following equations:
dPpat
dt
=
Qpas −Qpat
Cpat
(4.10)
dQpat
dt
=
Ppat − Ppvn − (Rpat)Qpat
Lpat
(4.11)
where Rpat, Lpat and Cpat are the resistance, inductance and the compliance
of the pulmonary artery compartment, respectively. Ppat and Ppvn represent the
pressure of the pulmonary artery and pulmonary vein compartment, respectively.
Figure 4.7 represents the systemic block diagram. The systemic block dia-
gram is further divided into three block diagrams including the aortic sinus, the
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Figure 4.10: Renal circulation compartments.
aortic arch and the lower limbs compartments. Figure 4.8 shows the pulmonic
circulation. The pulmonic diagram is divided into three block diagrams includ-
ing the pulmonary sinus, the pulmonary artery and the pulmonary vein. In this
study, in order to investigate the hemodynamic responses of the upper and the
lower extremities to the pump, the carotid circulation and the renal circulation
compartments have been added to the systemic loop, as shown in Figure 4.1.
Each block diagram in the systemic, pulmonic, renal and the carotid circula-
tions is modelled according to Equations (4.10) and (4.11). However the input
parameters vary depending on the dynamics of each compartment in the native
cardiovascular system. The input parameters for the systemic, pulmonic, renal
and the carotid circulations are presented in Table 4.4.
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4.2.3 Numerical Model of the MCS Device
The typical operating condition for an MCS device in the descending aorta, in
series with the heart, is 24± 10 mmHg against 10 lt/min [53, 60, 61]. Here, the
prototyped rotary pump B simulating an MCS device with a wide range of rotor
speeds (2400-5400 rpm) was employed. More details on the pump description can
be found in Chapter 2 of this thesis. Figure 4.11 shows the graph of pressure
flow-rate relationship of the prototype MCS device at different rotor speeds.
Figure 4.11: Pressure gradient (mmHg) verses flow-rate (lt/min) for the prototyped pump
B. The pressure gradient against flow-rate were recorded in a non-pulsatile loop at each pump
rotor speed, while the circuit resistance was increasing.
For the numerical study, the MCS device is modelled by fitting the pressure
flow-rate curves into the Look-Up-Table function integrated in Simulink envi-
DelP
1
lt/min
-K-
Switch
1
Lookup
Table (2-D)
Qarao (ml/s)
2
w(rpm)
1
Figure 4.12: Block diagram of the pump in the Simulink environment.
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ronment of the MATLAB program. Referring to the electric-fluid analogy, with
the pump in series configuration, the aortic arch flow-rate (Qarao) is taken as
the input value to the pump and the pressure difference across the pump is the
output. This is in contrast with modelling of the in-parallel configurations where
the pressure difference was taken as the input parameter and the flow-rate was
the output [81, 102, 103, 136, 137, 138, 139].
QMCS = Qarao (4.12)
The pressure difference across the pump is calculated simultaneously in terms of
Qarao and the rotor speed (ω) value using an in-built interpolation-extrapolation
process of Look-Up-Table function, as shown in Figure 4.12. The output pressure
across the pump is incorporated into the system, as shown in Figure 4.1, and
ultimately induces the flow throughout the whole CLP model.
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Table 4.4: Parameter of the blood vessels for the CHF condition.
Part Parameter Value
Systemic Csas(ml/mmHg) 400
circulation Carao(ml/mmHg) 0.1
Rarao(mmHg s/ml) 0.8
Larao(mmHg s0.5/ml) 0.0017
Varao(ml) 41.6667
Clol(ml/mmHg) 400
Rlol(mmHg s/ml) 2.5
Llol(mmHg s
0.5/ml) 0.1
Rsar(mmHg s/ml) 2.5
Rscp(mmHg s/ml) 2.5
Vlv0(ml) 5
Pulmonary Cpas(ml/mmHg) 400
circulation Rpas(mmHg s/ml) 2.5
Lpas(mmHg s0.5/ml) 0.1
Cpat(ml/mmHg) 400
Rpat(mmHg s/ml) 2.5
Lpat(mmHg s0.5/ml) 0.1
Rpar(mmHg s/ml) 2.5
Rpcp(mmHg s/ml) 2.5
Rpvn(mmHg s/ml) 2.5
Cpvn(ml/mmHg) 400
Cpvc(ml/mmHg) 400
Vrv0(ml) 5
Carotid circulation Cca(ml/mmHg) 0.01
(Carotid artery Rca(mmHg s/ml) 0.8
and Brain) Lca(mmHg s0.5/ml) 0.0017
Vca(ml) 57.9150
Rcereb(mmHg s/ml) 0.8
Csvn(ml/mmHg) 11.8196
Rsvn(mmHg s/ml) 1.0100
Lsvn(mmHg s0.5/ml) 0.0017
Vsvn(ml) 100
Renal circulation Cren(ml/mmHg) 11.8196
(Renal artery Rren(mmHg s/ml) 0.1422
and Kidneys) Lren(mmHg s0.5/ml) 0.0033
Vren(ml) 100
Rkid(mmHg s/ml) 0.1422
Rivn(mmHg s/ml) 2.5
Civn(ml/mmHg) 400
Civc(ml/mmHg) 400
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4.3 Experimental study
The objectives of experimental test are met by using our in-house multi-chamber
simulator of the cardiovascular blood flow loop (SCVL). Figure 4.14 shows the
photograph of the multi-chamber SCVL which has been elaborated inChapter 2.
Following tasks were performed to reproduce the diseased condition.
• The circulating volume of water is increased.
• Dlvmin is increased by 20% in order to increase the resting left ventricle
volume.
• Dlvmax is decreased by 20% with the purpose of mimicking the reduced left
ventricle pumping ability.
Figure 4.13 represents a comparison between the slider’s maximum and mini-
mum displacement while simulating a healthy and diseased condition.
Figure 4.13: Schematic representation of the linear motor, actuating the left ventricle cham-
ber.
The experimental measurements for the CHF condition were validated with
the corresponding clinical data [2, 4, 141]. In each case, the aortic pressure, left
ventricle pressure, carotid pressure waveforms as well as the average CO were
recorded.
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Figure 4.14: Photograph of the SCVL system with the pump in the descending aorta, LM: Linear Motor, LA: Left Atrium, LV: Left
Ventricle, RA: Right Atrium, RV: Right Ventricle, C: Compliance, R: Resistance, F: Flow meter, PT: Pressure Transducer.
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4.4 Results and Discussion
For the experimental test, the replication of the in-series configuration was con-
ducted by placing the pump in the proximal descending aorta, below the Subcla-
vian artery and above the renal arteries, as shown in Figure 4.14. Subsequently,
for the numerical test, the Look-Up-Table function was incorporated into the
CLP model as shown in Figure 4.1. In this experiment, to observe the ultimate
hemodynamic responses of the SCVL system in the presence of the MCS device,
the pump was run at its maximum rotor speed of 5400 rpm.
Figure 4.15 shows two consecutive cycles of the experimental and numerical
differential pressure (∆P) of pump B operating in the descending aorta, while the
SCVL system is in operation. It is shown that the maximum differential pressure
across the pump (∆Pmax=32 mmHg) occurs at the end-diastolic pressure (points
1), whereas the minimum differential pressure (∆Pmin=25 mmHg) occurs at the
end-systolic pressure (point 2) of the first cardiac cycle.
It is evident that after point 1, upon the opening of the aortic valve, the exper-
imental and numerical pressure traces fall down sharply with a good agreement
until they reach to point 2 where the aortic valve closes. From point 2 toward
point 3, where the second cardiac cycle begins, the numerical trace rises smoothly
whereas the experimental trace does not follow the numerical trend accurately.
This discrepancy can be interpreted due to the implementation of the air/water
compliance units replicating viscoelastic feature of the cardiovascular system. It
is also evident that as a result of the pump vibration, a number of high frequent
oscillations are appearing during each cardiac cycle. Although the presence of
the transient oscillations is not a major concern in our in-vitro test, in future
studies it will be significantly reduced with the application of a higher grade
bearing system. Considering the pressure flow-rate relationship of the pump in
Figure 4.11, for the pump differential pressure changing from 32 to 25 mmHg,
the corresponding flow-rates of 1.8 and 4.5 lt/min can be extracted resulting in
an improved averaged flow-rate of 3.5 lt/min of the cardiac output.
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Figure 4.15: Experimental and numerical dynamic differential pressure of the MCS device
operating in the descending aorta.
Figure 4.16(a) and Figure 4.16(b) show the experimental and numerical simu-
lation as well as the corresponding clinical data [4] of the Aortic Pressure (AoP)
waveforms for the CHF condition before and after the MCS device insertion
in the descending aorta. It is evident that for the CHF condition the AoP is
102/79 mmHg and with the pump in operation the AoP has lowered to 80/50
mmHg. It is observed that with the pump in operation the aortic pulse pressure
(AoPP) has improved from 24 mmHg for the CHF condition to 29 mmHg with
the pump in operation. The improved pulse pressure is in agreement with those
studies [40, 41, 42] that emphasize on the pulsatility as a beneficial aspect for
end-organ functionality.
As shown in Figure 4.16(a), during the systolic and diastolic phases of the car-
diac cycles the numerical and experimental simulations are in fair agreement with
the corresponding clinical data [4]. The small bump reflected on the descending
limb of the AoP waveform is known as dicrotic notch (Incisura) occurring due
to the aortic valve closure at the pressure of 93 mmHg. It is evident that the
dicrotic notch on the experimental trace is slightly larger compared to the one
appearing on the clinical as well as numerical traces. This can be justified due to
the inherent rigidity of the replicated aortic valve leaflets which responses slightly
different from the biological valves in a native system.
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In Figure 4.16(b), the small transient pressure oscillations appearing on the
AoP waveform are due to the vibration occurring during the pump operation. It
is also evident that the dicrotic notch is less obvious than the one for the CHF
condition. This is mainly due to the pressure drop generated upstream of the
MCS device that avoids the aortic valve of being fully closed.
Figure 4.16: (a) Experimental, numerical and clinical [4] AoP for the CHF condition. (b)
Experimental and numerical AoP with the pump in the descending aorta.
Figure 4.17(a) and Figure 4.17(b) show the experimental as well as the nu-
merical simulation of the Left Ventricle Pressure (LVP) waveforms for the CHF
condition before and after the MCS device insertion in the descending aorta, re-
spectively. It is evident that for the CHF condition the LVP is 104/28 mmHg
and with the pump in operation the LVP has lowered to 80/10 mmHg.
In Figure 4.17(a), the small pressure bump reflected just before the ascending
limb of the LVP waveform represents the systolic atria contraction occurring at
the end of the cardiac filling phase in a native system. It is evident that at
the LVP of 100 mmHg, a significant oscillation is appearing on the experimental
trace. This is regarded as the hammer effect which is due to the sudden closure
of the rigid leaflets of the mechanical valve [86].
As shown in Figure 4.17(b), due to the pressure drop generated upstream of
the pump, the end-diastolic pressure of the left ventricle (LVPdia) has dropped
to the level of 10 mmHg. A drop in LVPdia leads to a lower volume expansion
4 Numerical and in-vitro Investigation of a Novel MCS Device
Installed in the Descending Aorta 139
and thus lower ventricular wall stress during the filling phase in a native system.
This may assist with the recovery of the damaged myocardial cells in an impaired
heart [144].
Figure 4.17: (a) Experimental and numerical LVP for the CHF condition, (b) Experimental
and numerical LVP with the pump in the descending aorta.
Figure 4.18(a) and Figure 4.18(b) show the experimental and numerical simu-
lations as well as the clinical data [141] of the Carotid Pressure (CaP) waveforms
for the CHF condition before and after the MCS device insertion in the descend-
ing aorta. Figure 4.18(a) shows that for the CHF condition the CaP is 110/76
mmHg and with the pump in operation, as shown in Figure 4.18(b), it has lowered
Figure 4.18: (a) Experimental, numerical, clinical [141] CaP for the CHF condition, (b)
Experimental and numerical CaP with the pump in the descending aorta.
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Figure 4.19: (a) Numerical time histories of the left ventricle output flow with and without
the pump, (b) Numerical time histories of the right ventricle output flow with and without the
pump, (c) Numerical time histories of the renal artery flow with and without the pump, (d)
Numerical time histories of the carotid artery flow with and without the pump. (e) Numerical
time histories of the coronary artery flow with and without the pump. (f) Numerical diagram
of the pressure-volume loop with and without the pump.
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to 105/48 mmHg. It is evident that the pressure drop generated upstream of the
pump alleviates the end-diastolic carotid pressure (CaPdia) substantially from 76
mmHg for the CHF condition to 48 mmHg, leading to a rise in the carotid pulse
pressure (CaPP) from 40 to 54 mmHg.
Figures 4.19(a-f) show the numerical flow-rate past the aortic valve, the pul-
monic valve, the renal arteries, the carotid artery and the coronary arteries in
the presence of the pump in the descending aorta. As shown in Figure 4.19(a),
with the pump in operation, the peak flows past the aortic valve (Qao,peak) has
increased from 450 to 650 ml/s. Similarly, as shown in Figure 4.19(b), there is
an improvement in the peak flows past the pulmonic valve (Qpo,peak) from 290 to
420 ml/s. In both Figures 4.19(a-b), a slight aortic and pulmonic back flow can
be appreciated by negative value of the flow occurring during the aortic and the
pulmonic valve closure, respectively.
The experimental flow records are in good agreement with the numerical re-
sults. It has been shown that with the pump operating at 5400 rpm in the de-
scending aorta of the SCVL system, the average cardiac output and the average
pulmonic flow have increased by about 40 and 50%, respectively.
Figure 4.19(c) shows that the renal artery flow-rate (Qren) has increased by
28% with the pump operating in the descending aorta. The mean renal artery
pressure (Pren) was recorded on the SCVL system. It was observed that the Pren
improved from 76 mmHg for the CHF condition to 90 mmHg with the pump in
operation. In a native system, the renal perfusion is not autoregulated unless
the Pren is greater than 85 mmHg [10]. It is further demonstrated by Zanardo et
al. [145] that the pressure rise in the renal artery may improve the renal function
in patients suffering from the kidney failure.
Figure 4.19(d) shows that with the pump operating in the descending aorta,
the carotid artery flow-rate (Qca) has dropped by 14.3% and the experimental
result showed a drop of 16.6% in QRca with the pump operating at 5400 rpm.
However, it must be noted that in a native human cardiovascular system, cerebral
blood flow is well auto-regulated within 60-140 mmHg of AoPmean and the local
blood flow feedback control provides enough blood perfusion within this limit [53,
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60, 61].
Figure 4.19(e) shows that the coronary artery flow-rate (Qcor) has decreased
by 12% with the pump operating in the descending aorta. Similar to the carotid
perfusion, it must be noted that in a native system the coronary perfusion is
controlled via a complex auto regulation mechanism that is dependent on the
myocardial oxygen demand [10]. As indicated in the present study, with the pump
operating in the descending aorta, the left ventricular internal pressure decreases
dramatically implying that the myocardial oxygen demand to overcome the after
load pressure may drop subsequently. It is evident that a declined heart oxygen
demand will have a significant effect on the coronary autoregulation which may
compensate the coronary perfusion in a native system.
Figure 4.19(f) represents the numerical diagram of the left ventricular Pressure
versus Volume (PV-loop) for the CHF condition with and without the pump.
The PV-loop is a useful approach of representing the cardiac performance [10].
By referring to the CHF PV-loop, it is observed that during the iso-volumetric
contraction phase the maximum ventricular pressure, just before opening of the
aortic valve, is 82 mmHg (point (a)), implying that the impaired heart needs to
consumes a lot of energy for increasing the ventricular pressure to overcome the
elevated after-load pressure, so less energy remains for the ejection phase. With
the pump in operation, the MCS PV-loop shows that the maximum pressure has
dropped to 57 mmHg (point (a´)), indicating that more energy is consumed for the
ejection phase. During the ejection phase, with the pump in operation the stroke
volume has increased from 45 to 51 ml. During the iso-volumetric relaxation with
the pump in operation the ventricular pressure has dropped subsequently. This
may help with the elastic recoil of the ventricle in a native system [10]. Finally,
during the filling phase, it is evident that the end diastolic volume has decreased
from 133 ml (point (b)) to 116 ml (point (b´)) with the pump in operation.
Table 4.5 represents the hemodymanmic responses of the CLP model as well
as the SCVL system to the pump operating in the descending aorta.
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Table 4.5: Hemodynamic results of the cardiovascular system with the MCS device integrated
in the descending aorta.
Parameters Baseline MCS Units
LVPsys 102 82 mmHg
LVPdia 25 17 mmHg
LVPvalve,open 82 57 mmHg
AoPsys 102 82 mmHg
AoPdia 76 53 mmHg
AoPmean 84.7 62.7 mmHg
AoPP 26 29 mmHg
CaPsys 108 102 mmHg
CaPdia 68 48 mmHg
CaPmean 81.3 66 mmHg
CaPP 40 54 mmHg
Pren,exp 76 90 mmHg
LVVsys 88 65 ml
LVVdia 133 116 ml
SV 45 51 ml
Qao-peak 540 650 ml/s
Qpo-peak 430 525 ml/s
Qren-peak 18 23 ml/s
Qca-peak 17.8 15.5 ml/s
Qco-peak 1.75 1.6 ml/s
Qpo,exp 2 3.1 lt/min
Qao,exp 2.5 3.5 lt/min
∆Pmax - 32 mmHg
∆Pmin - 25 mmHg
QRca,exp - -16.6 %
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4.5 Summary
Traditional implantation techniques from the apex of left ventricle to the ascend-
ing or descending aorta are highly invasive and carry substantial complications for
end-stage heart failure patients. This study has shown that the descending aorta
can be a promising location to install a long-term implantable mechanical circu-
latory support with minimally invasive surgery. Herein, the hemodynamic effect
of an in-house prototyped pump implanted in the descending aorta was investi-
gated numerically as well as experimentally. The objective of the experimental
study is met by using the in-house simulator of the cardiovascular loop replicat-
ing congestive heart failure condition. The objective of the numerical study was
met by using the modified version of the concentrated lumped parameter model
developed by the same team. The results show that the pump placement in the
descending aorta can lead to an improvement in pulsatility. The pressure drop,
generated at the upstream of the pump, facilitates the cardiac output as a re-
sult of after-load reduction but at the same time, it induces a slight drop in the
carotid perfusion. The pressure rise, generated at the downstream of the pump,
improves the blood perfusion in the renal circulation.
Chapter 5
Conclusions and Future Work
5.1 Conclusions
Despite a significant improvement in long-term results, the use of MCS devices is
still associated with considerable post-operational complications such as infection,
bleeding and end-organ failure. It is reported that many of these physiological
complications are due to prolonged invasive implantation procedures in critically
ill patients. Therefore, less invasive alternative techniques have become an area
of research interest.
Although an in-vivo test has been recognised as the most reliable approach to
investigate the hemodynamic responses of cardiovascular systems, the uncontrol-
lable environment of an in-vivo experiment results in significant uncertainties and
complications. In contrast, an in-vitro simulation of the cardiovascular system
which can emulate the characteristics of the native cardiovascular system not
only simulates the required hemodynamic response but also avoids a number of
complications that can occur in an in-vivo test. These in-vitro simulations can be
classified as numerical or experimental. This thesis investigated the feasibility of
MCS device implantation in the descending aorta using both experimental and
numerical approaches.
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As presented in Chapter 2, for the experimental investigation a Simulator of
CardioVascular Loop (SCVL) was designed and developed. This system included
models for all four chambers of the heart, and the systemic and pulmonary circu-
lation loops. Each heart chamber was accurately activated by a separate linear
motor to simulate the suction and ejection stages, thus capturing important fea-
tures of the perfusion waveforms. Four mechanical heart valves corresponding
to the mitral, pulmonary, tricuspid and aortic were used to control the desired
unidirectional flow. The experimental results showed the feasibility of emulating
different physiological and pathological conditions of the human cardiovascular
system with this SCVL system. This was achieved by controlling the different
parameters of blood circulation through the vascular tree, mainly the resistance,
compliance and elastance of the heart chambers.
The experimental test on the feasibility of MCS implantation into the descend-
ing aorta in series with the heart and a comparison with two in-parallel config-
urations of LV-AA and LV-DA was presented in Chapter 3. It was concluded
that the implementation of the LV-AA configuration results in the most signif-
icant improvement in the systemic and pulmonic flow perfusion. However, this
approach requires more invasive surgery than other configurations. The LV-DA
configuration is less invasive compared to the LV-AA configuration, but the LV-
DA configuration was not considered as optimal due to the flow retrogradations
in the aortic arch at high levels of MCS support. In both in-parallel approaches
(LV-AA and LV-DA), increasing the level of MCS support led to a decrease in
the aortic and the carotid pulse pressures to a certain extent. Finally, the use of
an MCS device in the descending aorta showed an improvement in the systemic
and pulmonic flow perfusion. In addition, it could lead to an improved haemo-
dynamic pulsatility which is beneficial for end-organ functionality in a native
cardiovascular system.
In Chapter 4, a numerical study on the in-series configuration was conducted
using a modified version of the Concentrated Lumped Parameter (CLP) model.
It was evident from the numerical results that the pressure drop upstream of the
pump facilitated the cardiac output as a result of afterload reduction. Further,
the pressure rise downstream of the pump improves the blood perfusion in the
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renal circulation. In addition, similar to the experimental results, numerical
studies showed that the generated pressure drop at the proximal part of the
descending aorta induced a slight drop in the carotid perfusion. However, in a
native cardiovascular system, the carotid perfusion drop may be autoregulated
by the brain.
In conclusion, the experimental and numerical results from this study suggested
that the in-series technique which is a less invasive procedure than the traditional
in-parallel approaches of LV-AA and LV-DA, could be considered as a feasible
configuration for long-term MCS devices. This technique can be considered for
implantation of miniatured long-term MCS devices in human body in near future.
However, extensive research is required to address the issues discussed in this
thesis, and further analysis is needed through an in vivo test.
5.2 Future Goals
In order to achieve more reliable results from the in-vitro testing as well as the
numerical simulation, a number of modifications are recommended for future
studies.
• In the present study, the SCVL represents a simplified model of a patient
suffering from CHF condition in a supine position only. Any changes in pos-
ture will impose additional hydrostatic pressure on the upper limbs which
may lead to the risk of morbidity or mortality. For future studies, it is
recommended that the pump will be equipped with a control system which
responds accordingly to any sudden change of local variables including the
flow and pressure. In addition, the effect of reflex mechanisms needs to be
integrated into both numerical and experimental models.
• In this investigation, an open-loop control system is employed to control
the position of the linear motors. This open-loop control system is capable
of accurately and independently controlling the displacement of each slider
5 CONCLUSIONS AND FUTURE WORK 148
according to the predefined time-varying elastance functions. Nevertheless,
simulation of desired pressure or flow signals through an open-loop control
system is not an easy task and it is mainly calibrated manually using a
trial and error process. As a result, the open-loop control system is not the
best option. For future studies, it is recommended to integrate a closed-
loop proportional-integral control system. The closed-loop control system
is more accurate than the open-loop control system and it performs well for
multi-variable systems.
• In the present study, the systemic and pulmonic resistances are replicated
using a number of clips, adjusted manually to simulate different physiologi-
cal and pathological conditions. In future studies, the clips can be replaced
by proportional control pinch valves for a more adaptable system.
• The current multi-chamber SCVL system as well as our numerical model
do not include the auto-regulation mechanism for the cerebral and kid-
ney components. The numerical simulation and the in-vitro testing could
eventually be extended to include these mechanisms.
• During this experiment our cardiovascular simulator was under develop-
ment, so the use of animal blood or blood analog fluids (mixtures of water
and glycerine) was not feasible at this stage. It is evident that the viscos-
ity is considered as a profound parameter for the design of a rotary blood
pump, however it may not have a significant impact on the hemodynamic
responses of the SCVL system in the presence of the MCS device. For future
studies, it is recommended that a blood analogue fluid should be employed
to investigate haematological and thrombological blood complications.
Appendices
Publications:
Publications extracted from this research and my previous area of research are
listed as follow:
• Design of high-efficiency turbomachinery blades for energy conversion de-
vices with the three dimensional prescribed surface curvature distribution
blade design (CIRCLE) method. T. Korakianitis, I. Hamakhan, M. A.
Rezaienia, A. P. S. Wheeler, E. Avital and J. J. R. Williams. Applied
Energy, Vol 89, pp. 215-227, 2012.
• Aerodynamic improvements of wind-turbine airfoil geometries with the pre-
scribed surface curvature distribution (CIRCLE) blade design method, T.
Korakianitis, M. A. Rezaienia, I. Hamakhan, E. Avital and J. J. R.
Williams, Journal of Engineering for Gas Turbines and Power, Transac-
tions of the ASME, Vol 134, Issue 8, 2012.
• Two- and three-dimensional prescribed surface curvature distribution
(CIRCLE) blade design method for the design of high-efficiency turbines,
compressors and isolated airfoils. T. Korakianitis, I. Hamakhan, M. A.
Rezaienia and A. P. S. Wheeler, Journal of Turbomachinery, Transaction
of the ASME, Vol 135, Issue 3, 2013.
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• In vitro cardiovascular system emulator (bioreactor) for the simulation of
normal and diseased conditions with and without mechanical circulatory
support, P. Ruiz, M. A. Rezaienia, A. Rahideh, T. R. Keeble, M. T.
Rothman, T. Korakianatis, Artificial organs, 37(6):549-560, Jun 2013.
• In-vitro comparison of two different mechanical circulatory support devices
installed in series and in Parallel M. A. Rezaienia, A. Rahideh, M. T.
Rothman, S. A. Sell, K. Mitchell, T. Korakianitis, accepted for published
in the Artificial Organs Journal.
• Numerical and in-vitro investigation of a novel mechanical circulatory sup-
port device installed in the descending aorta. M. A. Rezaienia, A.
Rahideh, B. Alhosseini ,S. P. Zustiak, D. E. M. Bosak, T. Korakianitis,
accepted for published in the Artificial Organs Journal.
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